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Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor suppressor disorder
characterized by hamartomas, or benign growths, in various organ systems. Inactivating
mutations in either the TSC1 or the TSC2 gene cause most cases of TSC. Recently, the use
of ovarian specific conditional knock-out mouse models has demonstrated a crucial role of the
TSC genes in ovarian function. Mice with complete deletion of Tsc1 or Tsc2 showed
accelerated ovarian follicle activation and subsequent premature follicular depletion, consistent
with the human condition premature ovarian failure (POF). POF is defined in women as the
cessation of menses before the age of 40 and elevated levels of follicle stimulating hormone
(FSH). The prevalence of POF is estimated to be 1%, affecting a substantial number of
women in the general population. Nonetheless, the etiology of most cases of POF remains
unknown. Based on the mouse model results, we hypothesized that the human TSC1 and
TSC2 genes are likely to be crucial for ovarian development and function. Moreover, since
women with TSC already have one inactivated TSC gene, we further hypothesized that they
may show a higher prevalence of POF. To test this hypothesis, we surveyed 1000 women with
TSC belonging to the Tuberous Sclerosis Alliance, a national support organization. 182
questionnaires were analyzed for information on menstrual and reproductive function, as well
as TSC. This self-reported data revealed 8 women (4.4%) with possible POF, as determined
by menstrual history report and additional supportive data. This prevalence is much higher
than 1% in the general population. Data from all women suggested other reproductive
pathology associated with TSC such as a high rate of miscarriage (41.2%) and menstrual
irregularity of any kind (31.2%). These results establish a previously unappreciated effect of
TSC on women’s reproductive health. Moreover, these data suggest that perturbations in the
cellular pathways regulated by the TSC genes may play an important role in reproductive
function.
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Background
Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by
the formation of hamartomas, or benign growths, in various organs of the body. TSC is
estimated to affect 1/6000 – 1/10000 individuals. The disorder is caused by an inherited or de
novo mutation in either the TSC1 or TSC2 gene. Approximately 30% of cases are inherited
from an affected parent, and 70% represent de novo germline mutations. While TSC can
affect any organ system, major manifestations often occur in the brain, skin and kidney.
Approximately 50% of individuals will develop seizures and many have neuropsychiatric illness
and/or behavioral problems. TSC is diagnosed clinically, but molecular testing of TSC1 and
TSC2 is available for confirmation, accurate recurrence risks, and information for families.
History
The French neurologist Désiré-Magloire Bourneville is credited with naming tuberous
sclerosis, or, as he stated in 1880, “tuberous sclerosis of the cerebral convulsions
[Bourneville].” Bourneville described several findings in a deceased young woman with a
history of some degree of mental retardation, facial angiofibromas, and epilepsy since infancy.
Several sclerotic lesions in her brain were noted to be dense and “potato-like,” and Bourneville
concluded they were the likely cause of her seizures. He also noted masses in both of her
kidneys but believed they were independent of the brain pathology. The eponym Bourneville
disease was used well into the 20th century. The term Tuberous Sclerosis Complex is
attributed to Sylvan E. Moolten, who in 1942 proposed the name to reflect the heterogeneity of
the disorder. He also established “hamartoma” as the term for the pathologic tumors [Moolten].
The genetic etiology of TSC would not be uncovered until the early 1990s, but other
important genetic concepts were realized as early as 1910. Kirpicznik documented the
presence of TSC in three successive generations of one family [Kirpicznik]. Years later,
Gunther and Primrose confirmed the hereditary nature of TSC, and commented that a high
mutation rate must be present to account for the number of affected individuals with no family
history [Gunther]. Lastly, the term “forme frusta” TSC (from the French word for fluster, or
defaced) was used by Schuster to refer to those individuals who met some, but not all of the
existing diagnostic criteria. This early recognition of variable expression foreshadowed a
difficulty in the recognition and diagnosis of TSC that still exists today; fewer than 40% of
affected individuals meet the classic “triad” of seizures, mental retardation, and facial
angiofibromas [Kwaiatkowski; Curatolo, 2003].
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Early studies of TSC involved patients in mental institutions, and indeed the presence of
mental impairment was an initial part of TSC diagnostic classification [Chao]. However, a study
of individuals with TSC performed in the late 1960s showed over one third of individuals were
of average intelligence, and over 60% had some learning disabilities [Lagos]. This marked
phenotypic variability, contributed to multiple revisions of diagnostic criteria [Gomez; Roach,
1998; Roach, 2004]. The current diagnostic criteria for TSC are separated into major and
minor criteria. Individuals with two or more minor features or with one major feature alone are
considered “Possible TSC.” Those with one major feature and one minor feature are “Probable
TSC.” Finally, the presence of two major features or of one major feature plus two minor
features is deemed “Definite TSC.” These features are listed in the table below [Roach, 2004].
Major Features

Minor Features
Multiple randomly distributed dental

Facial angiofibromas or forehead plaque

enamel pits

Nontraumatic ungual or periungual fibromas

Hamartomatous rectal polyps

Three of more hypomelanotic macules

Bone cysts
Cerebral white matter radial migration

Connective tissue nevus

lines

Multiple retinal nodular hamartomas

Gingival fibromas

Cortical tuber

Nonrenal hamartoma

Subependymal nodule

Retinal achromic patch

Subependymal giant cell astrocytoma
Cardiac rhabdomyoma, single or multiple
Lymphangioleiomyomatosis
Renal angiomyolipoma

Manifestations
TSC has the potential to affect any organ system in the body. Descriptions of the most
common findings are presented below.
Dermatologic Lesions
Virtually all individuals with TSC have skin lesions that are often clues for the
diagnostician. Hypopigmented macules, the most common skin findings, are present in nearly
all individuals. These lesions usually have a sharp border, are elliptical, and show improved
2

visibility under a Wood’s light, which is useful for examining individuals with fair skin
[Fitzpatrick; Leung]. Importantly, in the absence of prenatal findings, hypopigmented macules
are often the first signs of TSC, as they are present at birth. The next most common
dermatological lesions are facial angiofibromas, present in approximately 47-90% of affected
individuals. These typically do not appear until late childhood and early adolescence
[Curatolo]. The appearance of angiofibromas is often psychologically disturbing to patients.
Another skin finding, hypopigmented macule (previously “shagreen patch)” is present in 20% 80% of individuals. It is typically located in the lumbar region or the nape of the neck and often
appears with satellite lesions. The skin is usually leathery, and can be dimpled like an orange
peel [Webb].
Fibrous facial plaques are slow growing, raised, flesh-colored plaques seen in about 19%
of individuals [Jozwiak]. Finally, ungual fibromas occur in 17- 87% of individuals with TSC.
These are tumors of the fingernails and toenails and are found more commonly in the latter
[Osborne]. The fleshy lesions can occur underneath and/or around the nails.
Neurologic manifestations
The neurologic manifestations of TSC often cause the classic features of intellectual
impairment, epilepsy, and behavioral problems. These complications are the most common
causes of morbidity and mortality, severely affecting individuals’ quality of life. About half of
individuals with TSC have normal intellect. Between ten and fifteen percent do not have
seizures [O’Callaghan; Sparagana & Roach].
Intracranial lesions include cortical tubers (in 70% of individuals), subependymal nodules (in
90% of individuals), and subependymal giant cell astrocytoma (in 6 -14% of individuals).
Tubers are typically usually present at birth and can be numerous [Leung]. Subependymal
nodules are lesions lining the lateral ventricular system of the cerebral hemispheres. The
lesions are usually multiple and small, and rarely cause clinical problems [Leung; Roach,
2004].
Subependymal giant cell astrocytomas (SEGAs) are benign tumors located in the lateral
ventricles near foramen of Monro. It is hypothesized that they develop from sub-ependymal
nodules, and indeed, the histology of both lesions are indistinguishable. However, they can be
visualized if they sustain significant growth. There is a risk for SEGAs to lead to an obstruction
of CSF outflow and become symptomatic. Prior to improvements in imaging and guidelines for
routine screening, patients often presented with specific symptoms of acute hydrocephalus
3

such as headache, emesis, and altered visual and/or status. Current recommendations are
screening every two years in individuals over the age of 21 [Campen; Leung; Sparagana].
Infantile spasms, partial motor and generalized tonic clonic seizures are present in 8090% of individuals [Sparagana; Kandt, 2003]. Seizures are typically managed with epileptic
medications. For some, surgical resection allows a favorable long-term outcome [Romanelli].
Consistent with other features of TSC, there is a spectrum of severity in intellectual
dysfunction and behavioral disturbances. Approximately 50% individuals have intellectual
disability [Kandt, 2003]. Most, but not all mentally retarded children with TSC have seizures.
Conversely, many patients with TSC have seizures but not mental retardation [Leung;
Sparagana; O’Callaghan]. In general, an earlier onset of seizures, particularly infantile
spasms, confers a greater risk of intellectual disability [Prather]. Of note, earlier treatment is
associated with a better prognosis for learning development and seizure termination. One
small study found a seizure free status in 50%, normal or borderline mental development in
30%, and no mental retardation in ten children with an early diagnosis treated with vigabatrin
followed long-term [Bombaradiere].
There are often specific learning difficulties in children with TSC. It is estimated that 25 50% of children with TSC have a diagnosis within autism spectrum disorder [Northrup].
Additionally, frequent behavioral disorders include attention deficit disorder, aggressive and/or
self-injurious behavior, hyperactivity, and sleep problems [Curatolo; Prather]. These may occur
in combination or as isolated problems [Leung; Roach].
Renal manifestations
The renal manifestations of TSC are the second most common cause of early death
[O’Hagan]. Angiomyolipoma (AML), the most common renal finding, is present in
approximately 70% of individuals. AMLs are often bilateral and progressively increase in size
and number. As the name implies, these growths are comprised of blood vessels, smooth
muscle cells, and adipose tissue [Henske]. Some degree of gender predilection exists in that
females are affected 3 to 4 times more often than males [Leung].
The second most common renal lesions are cysts, affecting approximately 50% of
individuals [Dixon]. Similar to AMLs, these may increase in size, and are usually numerous.
Cysts over 4 cm in diameter are often symptomatic and visible on CT scan [Roach, 2004;
Leung]. Individuals with a contiguous gene deletion involving TSC2 and PKD1, the gene
responsible for autosomal dominant polycystic kidney disease (ADPKD), will show symptoms
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of ADPKD such as hypertension, flank pain, and pyelonephritis, and are at increased risk for
end stage renal disease [Franz].
Lastly, renal cell carcinoma occurs in less than 2-3% of individuals, at an average age of
28 [Kwiatkowski, 2005; Patel]. The growth rate of carcinoma is much slower in TSC [Leung].
Ophthalmologic Abnormalities
Up to 75% of individuals with TSC have ocular findings. The most common finding is
retinal hamartoma, present in 40-50% of individuals. One-third of these patients will have
bilateral lesions [Leung].Lesions are best identified with pupil dilation and ophthalmoscopy.
The majority of lesions are asymptomatic, though they could lead to visual impairment if large
enough [Leung].
Cardiac Lesions
The most common cardiac manifestation in TSC is cardiac rhabdomyoma, present in 66%
of newborns. The maximum growth period occurs at 22-26 weeks gestation and thus is often
visualized in the third trimester of pregnancy. After infancy, these lesions are usually
asymptomatic and gradually disappear over time. Rarely, they result in outflow obstruction
(requiring surgery), valvular dysfunction, or arrhythmia [Leung].
Pulmonary Disease
In TSC, overall pulmonary dysfunction is infrequent. However, the most common finding,
lymphangioleiomyomatosis (LAM), may develop in up to 39% of women with TSC, typically at
ages 20-40 [Moss; Roach, 2004]. LAM is thus a well-established gender-specific manifestation
of TSC and mutations in TSC have been found in individuals with sporadic LAM [Carsillo].
Common symptoms of pulmonary disease include cough, dyspnea, hemoptysis, and
pneumothorax [Roach, 2004]. Disease can progress to the need for oxygen therapy and/or
lung transplantation.
Less commonly affected systems
A lesser known vascular manifestation of TSC involves aneurysm in the descending aorta,
primarily in the abdominal aorta [Cao]. Though rare, they occur more commonly in children
under the age of 5 years (the youngest reported at 4.5 months) and impart a risk for premature
death. Molecular correlation has identified at least one patient with a TSC2 mutation;
subsequent work in Tsc2 haploinsufficient mouse models demonstrated proliferation of smooth
5

muscle cells and reduced expression of contractile proteins [Cao]. The naturally occurring
“Eker” rat harbors a Tsc2 mutation and can develop pituitary adenomas, uterine leiomyomas,
splenic hemangiomas, lesions in the brain resembling SENs, cortical tubers, and renal tumors
[Wilson].
Also unappreciated is the extent of gender predilection in specific manifestations. AMLs
are more common in women with TSC in general, but also in women with TSC-associated
LAM compared to those with sporadic LAM. Estrogen and progesterone are thought to be
important in the development of these lesions. Additional effects of sex hormones or
reproductive manifestations in TSC are poorly understood. Perhaps further examination of
other possible organ manifestations will lead to the identification of newly appreciated
aspects of TSC.
Management
The severity of TSC is quite variable, and prognosis is based on each individual. As there
is no cure for TSC, management and surveillance are dependent on the symptoms present
and function to improve the patient’s quality of life. Routine evaluations include EEG to
manage seizures, cranial CT/MRI, renal ultrasonography and/or CT/MRI, echocardiography
when cardiac symptoms are present, behavioral evaluations, and chest CT if pulmonary
symptoms are present [Leung]. Recommended surveillance includes:
Individual

Surveillance

Frequency

Children/adolescents

Cranial CT / MRI

1-3 years

Individuals with no previously identified renal lesions

Renal ultrasound

1-3 years

Individuals with AML <3.5-4.0 cm

Renal ultrasound

Semiannually

Large / numerous renal tumors

Renal CT/MRI

As needed

Seizure management

EEG

As needed

If cardiac symptoms exist

Echocardiography

As needed

If pulmonary symptoms exist

Chest CT

As needed

Children entering school / in response to concerns

Neurodevelopmental
evaluations

As needed

As visual loss is uncommon, routine ophthalmologic evaluations are unnecessary for the
majority individuals with retinal lesions
Routine dermatological evaluations are unnecessary for most individuals.
Source: GeneClinics
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Inheritance
TSC is an autosomal dominant condition. Affected individuals have a 50% risk with each
pregnancy to have an affected child. Approximately one third of children diagnosed with TSC
have an affected parent while a majority (approximately two thirds) occur as a result of a de
novo mutation [Sancak; Rose]. TSC-causing mutations are fully penetrant, though TSC shows
marked variable expressivity within families and among individuals. Thus it is recommended
that the parents of a child with no family history of TSC be thoroughly evaluated. Some
individuals often have a very mild phenotype and/or could have eluded recognition from a
health care provider. The recurrence risk for parents with an affected child but no apparent
family history is complicated by somatic mosaicism [Verhoef].
Molecular Genetics
The TSC1 gene is located on the long arm of chromosome 9 (9q34) [van Slegtenhorst]. It
encodes the protein hamartin. Almost all TSC1 mutations are truncating. Over half are small
deletions and insertions, and 40% are nonsense mutations. Splice site mutations have also
been described; large deletions and missense mutations are rare [LOVD, TSC1]. Recently,
deletions in the promoter of TSC1 were identified by MLPA [Ouweland]. The TSC2 gene is
located on the short arm of chromosome 16 (16p13.3) and encodes for the protein tuberin
[European Consortium]. The majority of TSC2 mutations (64%) are small deletions and
insertions, splice site mutations, and nonsense mutations. Approximately 28% are missense
mutations, and the remaining 8% are due to large deletions or rearrangements; 3.7% involve
the PKD1 gene [LOVD, TSC2].
Approximately 20% of mutations identified occur in TSC1 and 60% in TSC2 [Crino]. The
remaining 20% of individuals have no identifiable mutations. There is a reportedly high rate of
somatic mosaicism in TSC, estimated between 10% and 25% [Verhoef]. However, a recent
study used deep sequencing analysis to identify mutations in affected individuals with possible
low-level mosaicism and concluded the rate of somatic mosaicism may be overestimated and
actually as low as 6% [Qin].
DNA testing is available clinically, but is not necessary for a diagnosis of TSC. Studies
have demonstrated an overall mutation detection rate as high as 85% in patients with a clinical
diagnosis [Sancak; Kwiatowski, 2010]. The majority of mutations in TSC1 can be detected
through sequence analysis. In general, the overall detection rate of TSC1 mutations is 30%
and 15% in familial and simplex cases, respectively. Sequence analysis of TSC2 has a
detection rate of approximately 50% in familial cases and 60-70% in simplex cases.
7

Deletion/duplication analysis comprises an additional 0.5% of familial cases, and 5% of
simplex cases [Northrup]. The detection of large deletions requires additional techniques, such
as Southern analysis or array comparative genomic hybridization (CGH).
Several studies have shown genotype and phenotype correlations [Au; Sancak]. TSC2
mutations are known to result in a more severe phenotype than TSC1 mutations and are more
common in individuals with de novo mutations. Familial TSC2 mutations and individuals with
de novo TSC1 mutations have a milder phenotype. Lastly, individuals for which no mutation
was identified also had milder phenotypes. In spite of these genotype-phenotype correlations,
mutational analysis should not currently be used for prognostic prediction [Jansen].
Pathogenicity
Hamartin and tuberin function as tumor suppressors. The pathogenesis of TSC involves
both the “two hit hypothesis” as well as haploinsufficiency. The former involves a loss of
heterozygosity (LOH). Complete loss of either TSC1 or TSC2 leads to a cellular loss of tumor
suppression and unregulated cell cycle progression, resulting in uncontrolled growth and the
development of hamartomas [Castro; Jozwiak]. A somatic “second-hit” mutation has been
best described in renal lesions, and LOH has also been observed in advanced stages of
murine renal lesion progression [Osborne Wilson]. The TSC genes have also been implicated
in individuals with sporadic lesions. In an analysis of AMLs taken from women with sporadic
LAM, TSC2 LOH was detected in six of seven AMLs [Niida].
Haploinsufficiency may be another explanation for the developmental of lesions.
Observations of renal tubules in mouse lesions have indicated a loss of heterozygosity (LOH)
in only about 20% of lesions, suggesting that haploinsufficiency may be sufficient to lead to
their development [Wilson]. As LOH is seen less frequently in cortical lesions, some have
proposed haploinsufficiency to explain the formation of some cortical lesions.
Hamartin and Tuberin form a biochemical complex that acts as a major regulator of capdependent translation in response to growth factors, energy status, oxygen tension and
mitogenic signals [Rosner]. This translational inhibition occurs at the level of the mTORC1
kinase, a key enzyme that controls the activation of multiple proteins of the translational
apparatus. The TSC complex inhibits mTORC1 through the GTP-ase activating domain of
tuberin on the RHEB protein, preventing mTORC1 mediated translation and cellular growth
(Figure 1) [Tee; Castro; Wang].
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TSC1 TSC2

PTEN

mTORC1

AKT

- Translation
- Cell Growth
- Proliferation

Figure 1. TSC and mTORC1. The TSC1/2 complex forms a heterodimer and inhibits
mTORC1 (bar), down-regulating cellular translation, cell growth, and proliferation. Separately,
mTORC1 is also inhibited by the action of PTEN. In contrast, AKT enhances mTORC1 activity
(arrow).

Separately, the TSC complex directly binds a second enzyme, mTORc2. This results in
the phosphorylation and activation of Akt [Tee; Castro]. As Akt is an oncogene implicated in
cancer formation, promoting such activity is a seemingly curious role for tumor suppressor
genes [Vivanco]. It is plausible that mutations in the TSC genes could accelerate tumor growth
through a loss of negative regulation on mTORc1, while a simultaneous loss of mTORc2
activity may attenuate Akt and could prevent hamartomas from becoming malignant [Huang].
Of note, mTORC1 is rapamycin-sensitive and responds to nutrients and energy inputs, and
mTORC2 is rapamycin-insensitive [Dann; Huang]. The potential for effective symptom
alleviation in TSC patients with rapamycin treatment is being explored [Koenig].

Mouse Models
Any organ system could potentially be affected by TSC. The use of conditional mouse
models has been important for the study of the roles of the TSC genes in TSC pathogenesis
and normal organ function [reviewed in Kwiatkowski, 2010]. Adkihari, et al., have examined
the role of Tsc1 and Tsc2 in the mouse ovary, an organ not thought to be affected in humans
9

with TSC. They created mice devoid of either Tsc1 or Tsc2 exclusively in the ovaries
[Adkihari, 2009, 2010]. These ovarian –specific knockout mice demonstrated premature
activation of primordial follicles and subsequent depletion of the ovarian reserve in young
adulthood, leading to infertility. In essence, these animals experienced the equivalent of the
disorder termed in humans as premature ovarian failure (POF).
These Tsc1 and Tsc2 ovarian specific knockout mice also showed sub-fertility; each
produced an average of 2 litters, significantly less than control mice with normal ovarian TSC
expression. The mice became infertile in young adulthood. Of note, despite accelerated
activation of primordial follicles, the size of the litters was unaffected.
The increase in follicular activation from loss of TSC function was associated with
increased mTORC1 activity, as demonstrated by increased phosphorylation of two
downstream substrates, p70 S6 kinase 1 (S6K1) and ribosomal protein S6 (rpS6).
Furthermore, treatment with the mTORC1 inhibitor, rapamycin, reversed the over-activation of
primordial follicles in knockout mice. Another ovarian specific knockout mouse model further
supports a crucial role for mTORC1 in ovarian biology. In mice lacking the expression of Pten,
a suppressor of mTORC1 upstream of the TSC complex (Fig 1), the entire primordial follicle
pool was activated and depleted in early adulthood, features of murine POF consistent with
the Tsc1 and Tsc1 ovarian specific knockouts. These results indicate elevated mTORC1
activity is the driving force of follicular activation, and that proper suppression from the TSC
heterodimer or other suppressors of mTORC1 activity is necessary to regulate appropriate
activation, maintaining dormancy of the follicular pool and preserving reproductive function.
These animal studies suggest that abnormal mTORC1 regulation might contribute to human
POF, a condition which remains largely idiopathic.

Premature Ovarian Failure (POF)
The studies discussed above indicate a crucial function of the TSC genes, and mTORC1
regulation, in murine ovarian function, but the extent to which human ovaries may be affected
from mutations in TSC1 or TSC2 is unknown. The authors concluded the knockout mice
underwent the phenotypic equivalent of POF. In humans, POF is defined as the cessation of
menses in a woman under the age of 40 and displays a clear disruption in the normal human
reproductive lifespan [Rebar, 2008]. Although widely used in the literature, the term POF may
be inaccurate, as it indicates a finality of menstrual functioning and fertility that is not
consistently observed. Other terms such as premature ovarian insufficiency, or POI, have
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been suggested, to account for a decline in ovarian reserve, and irregularities in menstrual
functioning concomitant with rising levels of FSH and reproductive symptoms such as hot
flashes [Rebar]. For the purposes of this reading, the term POF will be used throughout as a
term to refer to declining ovarian reserve, with the caveat that POI may indeed be more
representative of the menstrual issues subsequently discussed, particularly in the presence of
self-reported data and limited facts obtained in this study.
Ovarian function
The progression of a woman’s reproductive function begins prenatally, when millions of
follicles develop and are arrested at meiosis I in the developing gonads of the fetus [Altchek].
After reaching a maximal number of about 7 million at approximately 28 weeks, a decline of
follicles begins. At birth, 1-2 million follicles remain, declining further to approximately 200-300
thousand at menarche, less than 10% of the original supply. After menarche, a highly
regulated, cyclic process of ovulation is observed. At the age of 40, most women have about 8
thousand follicles remaining [Altchek]. This process continues until menopause, occurring at
an average age of 51 years.
Beyond the well described feedback mechanisms involving the hypothalamus, pituitary
gland, and ovaries, the oocyte itself governs a significant portion of ovulation in response to
highly controlled regulation of activation and development. However, as evidenced by the
previously mentioned mouse knockout studies, the mechanisms that govern the growth and
recruitment of follicles are poorly understood. The maintenance of dormancy in the ovaries is
required for the preservation of the follicular reserve; similarly, appropriate activation ensures
proper ovarian function, allows for pregnancy, optimal hormonal regulation, and ultimately,
ovarian senescence at menopause.
In each menstrual cycle, only one or two eggs are released during ovulation for the
approximately 40 years of reproductive lifespan. The majority of the remaining oocytes do not
reach a mature state, or are “recycled.” Thus, one can actually consider atresia the norm, and
ovulation a rarity. The rate of follicular atresia appears to increase with age. However, it is not
known whether increasing numbers of follicles undergo atresia prior to activation and growth,
accelerating the decline in follicular reserve, or if increasing numbers of follicles enter the
growth phase and thus undergo degradation in the absence of ovulation [Hansen]. Previously
the rate of follicular decline was thought to increase dramatically after age 38, when
approximately 25,000 follicles remain [Faddy]. This parallels the decline of fertility, which
peaks in the 20s and drops off substantially after age 35-38 [Menken]. However, recent
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evidence suggests the rate of decline is actually increasing constantly throughout life.
Therefore both a woman’s initial endowment of follicles and the increasing rate of atresia
leading to follicular depletion are responsible for a progression toward menopause [Hansen].
While menopause is a clear, well-defined end to a woman’s reproductive lifespan, it is
preceded by a dynamic process of a decline in ovarian function, occurring over several years.
These stages may involve sub-fertility, which often escapes detection because of adequate
and appropriate hormonal secretion [Hansen]. It is estimated that fertility begins to decline
approximately 10 years prior to the age of menopause, with an average of 41 marking the end
of fecundity [Murray]. Later, perimenopause occurs; this is a stage characterized by an
irregularity in menstruation cyclicity and increased gonadotropin levels. Additionally, the
number of follicles falls below a certain threshold (1000-1100) [Faddy]. Fertility is
compromised as many remaining oocytes contain chromosomal aberrations and make a
viable conception difficult. Eventually, there are no remaining follicles to allow for ovulation,
and menopause occurs.

Clinical Presentation and Diagnosis
The most common scenarios for POF evaluation include sub-fertility and menopausal
symptoms. Difficulty in conceiving often brings women to the attention of health care providers,
in the setting of an infertility specialist, obstetrician-gynecologist, or reproductive
endocrinologist. Others present with the onset of menopausal symptoms, including hot
flashes, dyspareunia, night sweats, and vaginal dryness [Altchek]. In particular, hot flashes are
a characteristic symptom of POF and are distinguished by their brevity, with an average
duration of 3.5 minutes. The hypothalamus senses a perceived discrepancy in set and core
temperature and quickly triggers homeostatic heat loss through increased heart rate,
perspiration, and vasodilation. In the general population, 85% of women overall will experience
hot flashes, 30% within three years of menopause [Kronenberg]. Additional indications include
oligomenorrhea, absence or regression of sexual secondary characteristics, ceasing birth
control pill without resolution of menstrual cyclicity, or after giving birth [Nippita].
Once POF is suspected, the clinician often pursues diagnostic testing such as a
progesterone challenge to distinguish between anovulatory states and hypothalamic
suppression [Rebar; Nelson, 2005]. Measurement of serum gonadotropin levels may also be
indicated. FSH and LH are elevated in POF, but must be measured on separate occasions at
least one month apart, as fluctuations in levels from intermittent ovarian activity can mask
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underlying disruptions [Shelling]. In addition, estrogen levels are typically low, approximately
50 pg/ml in women with an absence of functional follicles [Rebar]. Naturally, other reasons for
a lack of menstruation, such as pregnancy, thyroid abnormalities, polycystic ovarian
syndrome, and elevated prolactin must be excluded [Shelling; Rebar]. Lastly, a thorough
history is imperative in determining an etiology for POF, which is considered idiopathic for the
majority of women [Goswami, 2005]. A value of FSH over 40 IU/ml with concomitant
amenorrhea for 3-6 months (variable among physicians) is consistent with a diagnosis of POF
[deVos; Shelling].

Epidemiology
POF affects about 1% of the US population [Rebar]. The estimated prevalence increases
by a factor of about 10 with each decade of life, ranging from 0.1% at age 30 to 1% at age 40
[Rebar]. Some ethnic disparities exist: there appears to be a higher prevalence (1.4%) in
African-American and Hispanic women; the prevalence in Caucasians is about 1%; the lowest
figures, 0.1and 0.5%, are in Japanese and Chinese women, respectively [Nippita].

Etiology
In hypothesizing possible mechanisms of early ovarian decline, one appreciates the
complexity of the menstrual cycle. The time period for a primordial follicle to progress through
activation from dormancy, further follicular development, and selection for ovulation, atresia, or
rescue varies dramatically from days to decades [Altchek]. Additionally, there are many stages
of folliculogenesis or ovulation from which a depletion of significant magnitude may hasten the
progression to menstrual cessation. First, as early development of primordial follicles to
primary and pre-antral follicles occurs with each cycle, a smaller initial number of primordial
follicles to begin with would deplete the supply sooner. Atresia occurs concurrently at each of
these stages, resulting in a decreasing number of developing follicles maturing toward
ovulation. Thus, any increase in the rate of atresia will parallel the rate of decline in the
follicular supply. Thirdly, follicles must mature from the antral stage toward ovulation. Errors or
alterations in signaling, secreted factors, gonadotropin receptors, or numerous supporting
granulosa and thecal cells could all lead to ovarian dysfunction and early ovarian failure [Laml,
Persani]. Lastly, follicular damage or destruction from autoimmune factors or toxic effects from
excess metabolites could preclude successful follicle maturation [Nelson, 2009].
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Studies of POF have been hindered by the inaccessibility of the ovary and by the
occurrence of follicle depletion before symptom onset. A direct cause of POF remains
unknown in about 90% of cases [Nelson, 2009]. Broadly speaking, established etiologies
can be categorized into genetic conditions, autoimmune disease, exposures, postsurgical
complications, and other causes, and will be discussed below. [Strauss; Gravholt; Hundscheid;
Goswami; Laml].
Genetic
It is of no surprise that mutations in genes encoding proteins for the functions mentioned
above would be found in women with reproductive dysfunction. In fact, many mutations have
been found in small samples of women with isolated POF. Variants in gonadotropin receptors,
GDF9, NOBOX, NR5A1, Inhibin, FSH, POLG, AIRE, and FIGLA have been reported at low
frequencies [Laml; Persani].
Though comprising a small proportion of POF, the additive effect of genetic causes
accounts for approximately 5% of POF etiology [Shelling; Persani]. By far the largest part of
this is due to errors in the X chromosome.
Each female has two X chromosomes. Through a modification known as X-inactivation,
one X chromosome is effectively silenced in each cell. Studies have shown that while
differentiation of ovaries requires only one X chromosome, genes on the second X
chromosome function in ovarian maintenance [Laml]. Some regions of the X chromosome
accordingly “escape” inactivation and may be crucial for ovarian function, as evidenced by
POF and amenorrhea in women with breakpoints or deletions on the X chromosome including
Xp11.2-p22.1, Xq26-28, Xq13-22 [Laml; Conway]. It follows that global aberrations of the X
chromosome would be implicated in ovarian dysfunction, and indeed are present in 40-50% of
girls with primary amenorrhea and a portion of women with reproductive dysfunction. This
includes structural rearrangements such as translocations, mosaicism of sex chromosome
dosage, and aneuploidy such as Turner syndrome or triploidy.
Specific mutations in genes on the X chromosome can also lead to POF, the most wellknown being Fragile X syndrome. This is an X-linked mental retardation syndrome and the
most common cause of mental retardation in boys. Abnormal expansions of a CGG repeat in
the promoter regions of the FMR1 gene lead to abnormalities in gene methylation and gene
silencing. The inactivating expansion occurs when an allele containing between 55 and 200
CGG repeats is inherited from the mother [Chonchalya]. These intermediate sized alleles are
termed “premutation,” and carrier females have an absence of cognitive disease but an
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increased risk to pass on an expanded allele and have an affected boy [Corrigan]. The
frequency of POF in premutation carriers is estimated at 11.5% in those with a family history of
POF, and 3.2% in those with sporadic POF [Rohr].
The mechanism behind the increased frequency of POF in premutation carriers is
unknown, but is hypothesized as similar to that of Fragile X-related tremor/ataxia syndrome, a
neurological disorder that may present in premutation carriers. Expanded CGG repeats in the
5’ untranslated region of the gene shift the transcription start site upstream. A 5-fold elevation
of FMR1 mRNA may result in a toxic gain of function from a buildup of abnormal gene
products. It may lead to excess binding of proteins to the expanded repeat region, further
altering the translational efficiency; protein levels (FMRP) are known to decrease with
increasing repeat size [Hagerman]. Some have proposed that a cumulative effect of toxic RNA
may lead to increases in follicular atresia, leading to POF. Alternatively the FMRP-regulated
translational suppression on a subset of mRNA could lead to haploinsufficiency of proteins
needed in oocyte development [Rohr].
A diagnosis of POF, especially with a significant family history, warrants exploration of the
possibility of Fragile X. A 2006 statement from ACOG recommends that in a woman with
ovarian failure or elevated FSH level of unknown cause before 40 years “fragile X carrier
screening should be considered to determine whether she has a premutation” [ACOG].
More recently, chromosomal microarray has been utilized to identify copy number
variations in affected individuals. A recent study identified 44 losses and gains potentially
causative for POF in 74 patients. Many of the candidate genes are involved in meiosis, DNA
repair, and folliculogenesis or male fertility in homologs of model organisms [Ledig].
Autoimmune
Autoimmune disease contributes another significant portion of causes and may be present
in 10-20% of women with POF, often correlated with adrenal disease [Shelling]. These include
Addison’s disease, hypoparathyroidism, diabetes mellitus, pernicious anemia, vitiligo,
myasthenia gravis, autoimmune polyglandular syndrome types I and II, Crohn’s disease,
Sjogren’s syndrome, and systemic lupus erythematosus [Nippita].
Exposures
Radiation and chemotherapy for the treatment of malignant disease is one of the leading
causes of POF [Nippita; Rebar]. Chemotherapy depletes the number of oocytes, and affects
the structure and function of oocytes and granulosa cells. The risk to develop POF from
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radiation therapy is primarily from treatment within the pelvic area, but disruptions in the
hypothalamic-pituitary-ovarian axis must be considered. Of note, an additional factor of
importance involves the age at which radiation therapy occurs; prepubertal ovaries are fairly
resistant to radiation. Secondly, there is a dose-dependent effect, and the greatest risk for
ovarian failure occurs at doses of radiation 9 grays or higher [Nippita; Rebar]. Infection is
another possible cause of ovarian depletion. A study in 1998 demonstrated that 3.5% of
women with POF had varicella, shigella, or malaria exposure. In addition, some women may
develop oophoritis during an exposure to mumps [Goswami]. Other exposures leading to POF
may include surgeries, particularly in the pelvic region, that carry the potential to disrupt
vascular supply to the ovaries.
Other
Several reported associated causes of POF include cigarette smoking, epilepsy,
endocrine disruptors, and other environmental exposures, though these are equivocal and
poorly studied [Goswami; Conway]. Exposures to industrial 2-bromopropane, a cleaning
solvent, was associated with primary ovarian insufficiency in 16 Korean women [Nelson,
2000].
Management
The management of POF involves a combination of medical and psychological
assistance. A negative, often traumatic psychological impact has been consistently reported in
the literature, including social anxiety, depression, and lowered self-esteem [Rebar; Nippita;
Shelling; Schimdt; Liao; Groff; deVos]. Many women experience frustration from an inability to
recognize clinical reasons for their symptoms; one study found it took up to 5 years for a
diagnosis in a quarter of affected women [Albuzaidi]. Secondly, the term “failure” alone can
bring feelings of inadequacy and guilt [Nelson, 2005]. Indeed the rates of depression in women
with a diagnosis of POF seem to be higher than the general population. A recent study in 174
women with sporadic POF found the onset of depressive systems seemed to occur prior to the
actual diagnosis of POF but after the onset of symptoms [Schmidt].
It has been suggested that the term POF is inadequate to reflect the spectrum of ovarian
dysfunction, uninformative and difficult for patients, and to some degree, inaccurate [deVos;
Shelling; Rebar]. For example, in three studies, 50%–84% of women with POF had new follicle
growth and 16%–49% ovulated [Welt]. The term “primary ovarian insufficiency” is also used by
clinicians and was in fact the original term coined in 1942 by the endocrinologist Albright Fuller
[Rebar]. It is a vague term that allows for the heterogeneity and possible irreversibility of
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disease, and does not imply finality [deVos; Shelling; Rebar]. Additional terms include
“hypergonadotropic amenorrhea,” “hypergonadotropic hypogonadism,” and “primary
hypogonadism.” These terms may be less recognizable to patients, but also account for
etiologies outside of a defect in the ovaries [Shelling; Rebar].
A third psychological factor involves women who are seeking pregnancy at the time of
diagnosis. As increased numbers of women delay childbirth, the age of which childbearing is
most desired may be concurrent with the onset of POF [Shelling]. Estimates of the percentage
of women with POF who may still become pregnant range from 5-10% [Shelling]. However,
there are no known reliable predictors to identify these women, nor are there specific identified
measures to increase the chances of conception [deVos]. In fact, ongoing assessments of
patients have found that women with no oocytes observed by imaging have become pregnant,
while women with residual ovarian function have not [Dr. Michael J. Heard, personal
communication]. There is recent evidence that conception may occur with the suppression of
gonadotropin-releasing hormone (GnRH) analogues and subsequent ovulation induction, but
no published trials exist [deVos]. The lack of prognostic information makes it difficult for
clinicians to offer definitive information to women, and frustrating for patients who face the
possibility that they may not conceive.
The low chance of success in using a patient’s own oocytes for conception usually
prompts discussion of other pregnancy options for those women who desire children. Adoption
is certainly a choice for many families. More commonly, the use of donor eggs is utilized and
studies show higher success rates than those observed in traditional in vitro fertilization
[Rebar]. Appropriate counseling on familial risks of POF is essential, as many women choose
to have a family member, such as a sister, donate oocytes. Approximately 20-30% of women
have a family history of POF [Woad].
Additional management for patients involves mitigating the risks to the patient from a lack
of estrogen, which is important for bone health and reducing the risk of adverse cardiac
events. In studies of women with natural early menopause, the risk of mortality from
cardiovascular events was significantly higher than in women with late menopause, suggesting
that longer exposure to endogenous estrogen may be protective against cardiovascular
disease [van der Schouw]. A study of women with primary ovarian insufficiency demonstrated
a change in the lipid profile of patients, including elevated triglycerides and lower HDL
cholesterol concentrations [Knauff]. Evidence from longitudinal studies such as the Women’s
Health Initiative (WHI) have assessed risks for the development of breast cancer, heart
attacks, and strokes in menopausal women who had a prior hysterectomy undergoing
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hormone replacement therapy (HRT) [LaCroix]. There are marked differences in women who
have experienced natural menopause and patients with POF; the former are typically seeking
symptom alleviation, while the latter utilize HRT to counteract the deficit of estrogen [Shelling].
Recent releases from the WHI have indicated that the risks for breast cancer appear lower in
those women who received estrogen only after menopause, and younger estrogen users had
a lower rate of heart attacks [LaCroix]. Estrogen is also important in protection against
osteoporosis. In the absence of exogenous estrogen supplementation, routine bone density
scans, medication, and lifestyle changes are useful in preventing osteoporosis and a reduction
in bone mineral density [Woad; Shelling]. Finally, as autoimmune disorders are considered an
etiology of POF, approximately 20% of women with spontaneous POF will develop
autoimmune hypothyroidism [Kim]. Therefore, it is prudent to include measurements of TSH
and free T4 during a workup for POF, and to check for the presence of serum thyroid
peroxidase autoantibodies [Nelson, 2009].
Despite the mechanisms of POF identified through numerous studies among various
medical disciplines, diagnosis includes a direct cause in only a small portion of women. This
fact necessitates further attempts to understand disruptions to ovarian function, and the
eventual establishment of risk factors to identify women for which further attention is
implicated.
Goals of Project
As the majority of women are given a diagnosis of idiopathic POF, many are left with little
guidance on appropriate management and information for family members [Altchek].
Therefore, more information and research is necessary to pinpoint specific mechanisms of
POF in humans and identify possible genetic components to account for the relatively high
observed familial associations. Until recently there was no evidence to suggest the TSC genes
were crucial for follicular recruitment, survival, maturation, or demise. Recent evidence from of
Tsc1 and Tsc2 conditional knockout mouse models suggests otherwise. Identifying a possible
association between ovarian dysfunction and TSC-causing mutations is thus an appropriate
endeavor. The simplest way to assess the possibility of a connection between the TSC genes
and POF is to sample a selection of women with Tuberous Sclerosis Complex, since the
majority harbor a mutation in either TSC gene. Determining if an association between the two
conditions exists will shed more light on the function of the TSC genes and their possible
pathogenic role in the ovaries, and about mechanisms behind the pathogenesis of POF in
women. There is currently no evidence to suggest women with TSC have a higher incidence of
POF compared to the general population, or that the TSC1 and TSC2 genes play a similar role
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in human ovaries as was demonstrated in the mice [Adkihari]. The aim of this project is
establish a prevalence of POF and associated reproductive dysfunction in a sample of
women with TSC. We hypothesize that no significant association exists between women
affected with TSC and the likelihood of developing POF. Thorough self-reports of menstrual
function, reproductive history and symptoms, as well as clinical manifestations of TSC will be
collected from individuals. Expert medical guidance will be useful in determining which women
may have an unlikely, possible, or probable diagnosis of POF, or features pointing to perhaps
an occult and as of yet unrecognized problem. In the absence of a defined control population,
current scientific literature will be used to compare these women to what is reported about
POF in the general population. This information will allow for more interpretation of the results
of the conditional knockout mice studies, and further insight into possible roles of these genes
in human ovarian function.
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Materials and Methods
Participants
Participants were woman with tuberous sclerosis complex over the age of 18 who are
members of the national Tuberous Sclerosis Alliance (TSA) support group. This study, HSCGSBS-10-0329, was granted exempt status by the University of Texas Health Science Center
Committee for the Protection of Human Subjects. A total of 1000 questionnaires in return
addressed envelopes were sent to the TSA. These were sent to randomly selected women
from a database maintained by the TSA. Identifying information was only available to
members of the TSA and questionnaires were returned in blank, preaddressed envelopes.
Approximately one-fourth of the women to whom the questionnaire was sent were
“dependent,” meaning they are entered in the TSA database as individuals who live under the
care of another individual and thus the questionnaire was completed by a caretaker or family
member. We received a total of 200 questionnaires; five were blank, twelve were completed
with respect to an individual who was under the age of 18, and one was sent to an affected
male, giving a final sample size of 182. These individuals were excluded from analysis. An
email address was created in the event that women may have questions; one response was
received regarding the appropriate female in the household to complete the questionnaire. A
telephone number was also provided, and two women did make contact with questions and
concerns about the questionnaire; no information from email or telephone correspondence
was kept.
Questionnaire Design
The questionnaire was developed to encompass three areas: demographic
information, reproductive health and history, and information about the individual’s history of
TSC. In the absence of access to validated questionnaires assessing POF and without clinical
information from respondents, the questionnaire was designed through extensive literature
review and clinical expertise. Please see Appendix A for a complete questionnaire. A
description of the questions included in each section follows:
Demographics: Independent/proxy respondent, current age, height and weight,
ethnicity, employment status, marital status, household status, educational level, and annual
household income.
Reproductive Health: Age of menarche, age and number of pregnancies, live births,
and premature births, number of and ages at miscarriages, and number of terminations; a
detailed menstrual history from ages 16-40, indicating menstrual cycle regularity and the use
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of contraception; perimenopausal symptoms, blood tests indicating thyroid disease, elevated
testosterone levels, or a menopausal state; history and age of radiation therapy,
chemotherapy, hysterectomy, and/or oophorectomy; diagnosis (age, and by whom) of any of
the following: POF, polycystic ovarian syndrome (PCOS), Addison’s disease, Autoimmune
disease, Anorexia, Infertility, Turner syndrome, Galactosemia, Amenorrhea; a family history
(relation to individual, and age of diagnosis) of Fragile X syndrome, POF, and unspecified
autoimmune disorders; current medication, dose, and frequency.
TSC: Age of diagnosis, family history (relation to individual, and age of diagnosis, and
genetic testing (if pursued, and results, if known); history of a SEGA (type of treatment
received, if applicable); history of seizures (age of onset, frequency, and if surgery was
performed for seizure control); current and previous seizure medication (number of years
taken, and an indication of medication effectiveness on a 1-3 scale); diagnosis
(current/previous diagnosis and age of diagnosis) of any of the following: learning disability,
attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder, depression, dyslexia,
intellectual disability, obsessive compulsive disorder (OCD), other); clinical manifestations of
TSC (age of diagnosis, indication of current vs. prior manifestation, where applicable): facial
angiofibromas, hypopigmented macules, ungual tumors, renal cysts, angiomyolipoma, renal
cancer, pulmonary cysts, lymphangioleiomyomatosis, shortness of breath, rhabdomyomas,
and irregular heartbeat. Lastly, an opportunity for women to write in additional comments or
concerns was provided.
Menstrual Classification
Menstrual regularity was defined as 10 or more periods per year. Menstrual irregularity
was defined as 9 or less periods per year, or 0. Contraception was indicated by use of oral
contraceptive pills or an intrauterine contraceptive device. Time frames for age ranges of
menstrual history were divided into the following year increments: 16-20, 21-25, 26-30, 31-35,
36, 37, 38, 39, and 40. Women reported their history in regards to the majority (more than half)
of the time in each age range. Time frames in which women reported using contraceptives
were considered uninformative. For women reporting hysterectomy prior to age 40, only time
frames prior to the age of their hysterectomy were considered informative. Seven women
reported oophorectomy without hysterectomy; these were considered to be bilateral as the
women were no longer menstruating. The information gathered from the responses to the
menstrual history was classified into the following five categories:
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Group

Classification

0
1

All Regular
All Irregular

2

Regular to
Irregular

3
9

Number of informative
time frames
At least one
At least one
At least two

Alternating
Regularity
Unknown

At least two
None

Menstrual regularity
Regular in all time frames
Irregular in all time frames
Consistently regular in early time frame(s)
changing to consistently irregular in later
time frame(s)
Menses alternate between regularity and
irregularity, case not classified in Group 2
N/A

TSC Classification
Women reported specific manifestations in several organ systems and these were compared
to data in the current TSC literature to assess for reliability of data. The following
classifications were made:
Category
Dermatological

Renal

Pulmonary

Cardiac
Seizure

Manifestations
Facial Angiofibromas
Hypopigmented Macules
Ungual Tumors
Renal cysts
AML
Renal Cancer
Pulmonary Cysts
LAM
Shortness of Breath with Exertion
Rhabdomyomas
Irregular Heartbeat
History of Seizures

Statistical Analysis
Responses were entered into a password protected Microsoft Access database.
Descriptive analysis was performed for all variables (frequencies, means, median, range,
standard deviation, as applicable). All analysis was performed in Stata v.11 (College Station,
TX). Fisher’s exact t-test analysis was used with a significance p-value of <0.05.
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Results
Participants and Demographics
A total of 200 questionnaires were received for a response rate of 200/1000 (20%). Five
surveys lacked sufficient information, twelve surveys were completed with respect to
individuals under the age of 18, and one survey was sent to the household of an affected
male, resulting in a final sample size of 182. Participants were asked to indicate if the person
completing the questionnaire was affected with TSC (independent participant), or if they were
completing the questionnaire with respect to an affected individual (dependent participant). A
total of 42 women were dependent or this information was missing, and the remaining 140
were labeled independent. Demographic information for both groups is provided in Table 1.
The average age of independent participants was 44 years, and 35 years for dependent
women. The overwhelming majority of the study population (90.1%) indicated their ethnicity as
Caucasian. Differences in marital status, employment, educational level, and income between
independent and dependent participants are also provided. All women were presumed to have
a clinical diagnosis of TSC based upon their membership in the TSA. In spite of this
involvement, the questionnaire was constructed to further characterize TSC disease of the
participants. This data follows the reproductive data.
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Table 1. Demographic information for Independent and Dependent Women with TSC*
N=182
Independent / Dependent Status
n (% of total sample)
Independent
140 (76.9)
Dependent/ Unknown
42 (23.1)

Age
Median:
Range:

Caucasian
AfricanAmerican
Hispanic
Asian
Other

44 years
18 – 77 years

35 years
18 – 68 years

Dependent
Women
n (% of 42)

Independent
Women
n (% of 140)

Ethnicity
34 (81.0)

130 (92.9)

3 (7.1)

3 (2.1)

Part-time

14 (10.0)

6 (14.6)

0.0
2 (4.8)
3 (7.1)

1 (0.7)
1 (0.7)
5 (3.6)

Full-time
Student
Disabled
Retired
Other

64 (45.7)
6 (4.3)
10 (7.1)
10 (7.1)
7 (5.0)

4 (9.8)
2 (4.9)
6 (14.6)
1 (2.4)
2 (4.9)

Single
Married
Divorced
Widowed

Marital Status
37 (26.4)
82 (58.6)
16 (11.4)
5 (3.6)

37 (88.1)
4 (9.5)
1 (2.4)
0.0

Alone

Household Status
22 (15.70)

5 (11.9)

With family

81 (57.9)

25 (59.5)

Dependent
Women
n (% of 42)

Independent
Women
n (% of 140)

Employment Status
Unemployed
29 (20.1)
20 (48.8)

Annual Household Income
< $10,000
8 (6.6)
13 (37.0)
$10,000 – 24,000
12 (9.8)
8 (22.9)
$25,000 – 49,000 25 (20.5)
3 (8.6)
$50,000 -74,999
20 (16.4)
3 (8.6)
$75,000-99,999
21 (17.2)
2 (5.7)
> $100,000
16 (13.1)
1 (2.9)
Decline / blank
38 (27.1)
12 (28.6)
Highest Education Level
Under 12th grade
3 (2.1)
18 (43.9)
th
Completed 12
30
12 (29.3)
grade
(21.40)
Some college
43 (30.7)
6 (14.6)

With S/O
34 (24.3)
4 (9.5)
Assisted
Bachelor’s degree
0 (0)
7 (16.7)
living
Other
3 (2.1)
1 (2.4)
Master’s degree
* “Dependent” includes women for which this information was missing
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31 (22.1)

4 (9.8)

33 (23.60

1 (2.4)

Reproductive History
All information obtained in this study was self
self-reported
reported and thus reproductive information is
unconfirmed by medical chart review. Data are presented in Tabl
Tables
es 2 through 10 and
separated with respect to independent and dependent women. The study question of interest,
the prevalence of premature ovarian failure in women with TSC, is presented afterward.
The reported average age of menarche was 12.5 years and did not differ between
dependent and independent women (Figure 2). This age at menarche is consistent with that of
the general population and suggests initial menstrual function is intact in this population of
women with TSC. Though some degree of pub
pubertal
ertal irregularity is not uncommon, the majority
of cycles normalize by age 16
16-20. Thus, irregularity reported during the time period of 16-20

Number of women

years was still considered irregular even if followed by consistently regular cycles.
50
45
40
35
30
25
20
15
10
5
0

Mean: 12.47 years 1.6

7

8

9

10

11

12

13

14

15

16

17

18

Age (years)

Figure 2: Age of menarche of entire sample of Women with TSC
History of menstrual irregularity was determined by self
self-reported
reported cycle regularity, and use
of oral contraceptives, for five year intervals from 16
16-35,
35, and one year intervals from 36-40.
36
Women
omen were asked to report if cycles were regular or irregular for the majority of the time in
each category. Regular was defined as ““10 or more periods in a year,” and irregular was
defined as “less than 9 periods a year, or 0.” Oligomenorrhea is consisten
consistently
tly reported in the
literature as fewer than 9 periods in
n one year. Women with some irregularity were then divided
into those with only irregular cycles, women progressing from consistently regular to
consistently irregular periods, women progressing from consistently irregular to consistently
regular periods, and women whose periods alternated between regular and irregular cycles.
Of 182 women, 36 had a history that was uninformative because of unclear responses and
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oral contraceptive use. Nonetheless, 57 women (31.3%) displayed some irregularity in
menstrual cyclicity between the ages of 18 to 40 (Table 2).

Table 2. Menstrual History

Menstrual category

Independent
Women
N=140
n (%)

Dependent
Women
N=41
n(%)

Always regular
Always irregular
Regular to irregular
Irregular to regular
Alternating regularity
Uninformative

71 (50.7)
16 (11.4)
15 (10.7)
5 (3.6)
7 (5.0)
26 (18.6)

17 (41.5)
8 (19.5)
3 (7.3)
2 (4.8)
1 (2.4)
10 (24.4)

All women
N=181
n (%)
88 (48.6)
24 (13.3)
18 (9.9)
7 (3.9)
8 (4.4)
36 (19.8)

Pregnancy
Pregnancy data included a history of pregnancy, maternal ages at delivery of all live and/or
premature births, the number of miscarriages and maternal ages at occurrence, as well as the
number of voluntary terminations. 92 (50.1%) women indicated that they had become
pregnant. (Table 3) Of these, there were 10 women who had no live births, while a total of 8
women had premature births. The average number of pregnancies for women was 1.71, with
an average age of 25.3 years for the first pregnancy. Lastly, 3 of 18 total women who reported
a voluntary termination were dependent, and 15 were independent.

Table 3. Pregnancy

Women pregnant at any time
Average number of live births
Average age at first birth
(years)
Women who had preterm birth
Women who had voluntary
termination

Independent
Women
N=140

Dependent
Women
N=42

All Women
N=182

n (%)
85 (60.7)
1.7 ±1.5

n (%)
7 (16.7)
1.3 ± 1.0

n (%)
92 (50.1)
1.7 ±1.5

25.6 ± 5.5

21.8 ± 2.5

25.3 ± 5.4

7

1

8

3

15

18

26

Miscarriage
Of 92 women who reported ever being pregnant, 38 (41.3%) reported having a miscarriage
at one point in their life (Table 4). This rate of miscarriage is significantly higher than expected
when compared to national estimates from literature and US epidemiological data from
national surveys, which ranges from 15-25% for aged 25-39 years. Thirty-five of these women
were independent, and the remaining two did not indicate a dependent or independent status.
The ages at which the first miscarriage occurred varied from 19 to 40 with a mean of 28.5
years. The average number of miscarriages women reported was 1.6, ranging from one to six.
Menstrual history for these women is also provided in Table 4. Of women who had a
miscarriage, 34.2% had a history of some type of menstrual irregularity, while 50% reported a
history of consistently regular cycles. Six (17.1%) women with a history of miscarriage never
experienced a live birth, and 29 (82.9%) women with a history of miscarriage did have at least
one live birth.
Table 4. Miscarriage History for Women with TSC Reporting Pregnancy
N=92
Women who had at least one
miscarriage
n (%)
Average age of miscarriage (years)
Average number of miscarriages

38 (41.3)
28.5 ± 5.9
1.6 ± 1.1
Women with history of miscarriage

Menstrual category
n (% of women reporting pregnancy)
Always regular

19 (50)

Always irregular

4 (10.5)

Regular to Irregular

3 (7.9)

Alternating regularity

6 (15.8)

Uninformative

6 (15.8)

Reproductive symptoms, tests, and surgeries
The questionnaire was designed to screen for symptoms related to menopause, POF, and
other reproductive disorders, as well as a history of blood tests and surgery related to
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reproductive issues. We asked women who experienced reproductive symptoms to specify if
they occurred currently or in the past. We also asked them to specify a duration (in years) for
which these symptoms lasted (Table 5). We also inquired about blood tests indicating a
menopausal state, thyroid disease, or elevated testosterone levels (Table 6).
A surgical history of hysterectomy was reported in 38 women below the age of 40 (Table 7).
Eight women did not indicate an age at which this was performed, and were not considered
further as we had no means of evaluating their cycles. Additionally 18 women reported
oophorectomy at an average age of 42 years. Radiation therapy at unspecified locations was
reported in six women. One woman indicated use of radiation for SEGA, but the rest did not
indicate a diagnosis of cancer or other indications. The average age of radiation therapy was
31.7, reported by three women. One woman reported chemotherapy for an unspecified
indication, performed at 45 years.
Table 5. Reproductive Symptoms in Women with TSC Less Than 40 years
Independent Women

Symptom

Hot Flashes
Night Sweats
Body Hair
High Blood
Pressure
Milky breast
discharge,
excluding
breastfeeding
Weight gain
of 25 pounds,
excluding
pregnancy

Current or
previous
symptom
n (%)
7 (14.9)
N=47
10 (21.3)
N=47
8 (17.4)
N=46
12 (26.0)
N=46

Average
duration
(years)

5.8 ± 4.7
1.2 ± 0.5
12.3 ± 6.3
4.5 ± 3.0

Dependent Women
Current or
previous
symptom
n (%)
2 (7.7)
N=26
2 (7.7)
N=26
3 (11.1)
N=27
7 (25.9)
N=27

Average
duration
(years)

2.3 ± 2.5
2.3 ± 2.5
15.0 ± 7.1
12. ± 8.9

All Women
Current or
previous
symptom
n (%)
9 (12.3)
N=73
12 (16.4)
N=73
11 (15.1)
N=73
19 (26.0)
N=73

Average
duration
(years)

4.9 ± 4.4
1.5 ± 1.2
13.2 ± 6.0
7.7 ± 6.8

7 (15.2)
N=46

1.1 ± 1.3

1 (3.7)
N=27

--

8 (11.0)
N=73

1.1 ± 1.3

17 (35.4)
N=48

N/A

9 (33.3)
N=27

N/A

26 (34.7)
N=75

N/A
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Table 6. Reproductive Blood Tests in Women with TSC less than the age of 40
Dependent
Women
N (%)
1 (3.7)
N27
4 (14.8)
N=27
1 (3.7)
N=27

Independent Women
Blood Test Indicating:

N (%)
0 (0.0)
N=50
4 (8.0)
N=50
3 (6.0)
N=50

Menopausal State
Thyroid Disease
Elevated Testosterone
Levels

All Women
N (%)
1 (1.3)
8 (10.4)
4 (5.2)

Table 7. Surgical History of Women with TSC
Women Reporting Surgery Performed at Less Than the Age of 40

Surgery

n

Hysterectomy
Oophorectomy
Radiation therapy

31
14
0

Chemotherapy

1

Independent Women
% of
Average
Independent
Age
Women
(years)
N=140
(22.1)
35.6 ± 9.7
(10)
41.6 ± 7.4
--45

(0.71)

n
7
4
3

Dependent Women
% of
Average
Dependent
Women
Age (years)
N=42
(16.7)
26.6 ± 10.9
(9.5)
32 ± 5.3
(7.1)
31.7 ± 10.0

0

--

--

Other Reproductive Disorders
The presence of other reproductive disorders is presented in Table 8. Eleven women
reported a diagnosis of PCOS, at an average age of 32.4 years. Features associated with
PCOS can include menstrual irregularities, elevated BMI, and symptoms such as acne and
body hair. Additionally, the use of valproic acid is thought to be a risk factor for PCOS,
particularly in women with an elevated BMI. Twenty-one women reported using valproic acid in
the past, for an average of 5.33 years. Seventeen women reported current use of valproic
acid, for an average of 14.8 years. Of the 17 women currently using this medication, one did
report a diagnosis of PCOS. Other common disorders among the women were infertility and
autoimmune disease, present in 13 women each. Of note, 64 independent and 13 dependent
women in the entire sample indicated a family history of autoimmune disease. The menstrual
history classifications for these three diagnoses are presented in Table 9.
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Table 8. Reported Reproductive Diagnoses in Women with TSC
(not otherwise confirmed)

Diagnosis
POF

Independent Women
Average Age
n (%)
Diagnosed

Dependent Women
Average Age
n (%)
Diagnosed

4 (2.9)
N=135

0
N=37

39.3 ± 4.9*

11 (8.3)
0
32.4 ± 14.7
N=133
N=38
2 (5.3)
10 (7.5)
Amenorrhea
30.6 ±11.5
N=38
N=134
13 (9.6)
0
Infertility
30.9 ± 6.0
N=38
N=135
5 (3.7)
1 (2.6)
Anorexia
20.3 ± 1.5
N=135
n-38
1 (0.8)
0
Addison disease
41
N=134
N=38
13 (9.7)
0
Autoimmune Disease
36.6 ± 15.0
N=134
N=134
* One woman indicated an age at diagnosis of 45; this age was excluded
PCOS

N/A
N/A
Unknown
N/A
13
N/A
N/A

Table 9. Menstrual classifications of common reproductive diagnoses

Menstrual
Classification
Always Regular
Always Irregular
Regular to Irregular
Alternating
Regularity
Uninformative

PCOS
N=11

Infertility
N=13
n (%)

Autoimmune
N=13

4 (36.7)
2 (18.2)
0

5 (38.5)
1 (7.7)
4 (30.8)

8 (61.5)
2 (15.4)
0

2 (18.2)

2 (15.4)

2 (15.4)

3 (27.3)

1 (7.7)

1 (7.7)
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Medication
Women were asked to list the current medications they were taking, including frequency
and dosage. The classes of medications are listed in Table 10; we did not have information
about specific indications for each woman’s prescriptions. Data on seizure medications are
presented subsequently. On average 80.8% of women took medications. Outside of
multivitamins and supplements, the most common medications for independent women were
analgesics, followed by medications for high blood pressure, and psychiatric illness. For
dependent women, the most common were those for high blood pressure, gastric reflux, and
psychiatric illness.

Table 10. Current Non-Antiseizure Medications

Number of women
reporting current
medication
Average number of
medications used

Type of Medicine
Analgesic
Anti-histamine
Anti-microbial
Asthma-related
Bisphosphonate
Contraceptives/HRT
High Blood Pressure
Multivitamin
Other
PPI/GERD
Psychotropic
Statin
Steroids
Supplement
Thyroid hormone

Independent Women

Dependent Women

111 (79.3%)
N=140

36 (85.7%)
N=42

4.7 ± 4.0

3.8 ± 2.66

Number of
Women
40
2
10
21
8
29
39
39
38
14
52
29
18
51
23

% of 111
(28.6)
(1.4)
(7.1)
(15)
(5.7)
(20.7)
(27.9)
(27.9)
(27.1)
(10)
(37.1)
(20.7)
(12.9)
(36.4)
(16.4)
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Number of
Women
2
6
3
6
0
5
15
10
20
12
18
2
4
15
7

% of 36
(5.6)
(16.7)
(8.3)
(14.3)
(0)
(13.9)
(41.7)
(27.8)
(55.6)
(33.3)
(50)
(5.6)
(11.1)
(35.7)
(19.4)

TSC History
Age at Diagnosis
The reported age of diagnosis of TSC varied widely. Some women were diagnosed
prenatally, whereas one
ne person was diagnosed as late as 62 years of age. The median age of
diagnosis was 15 years. Frequencies and stratification by independent and dependent status
are provided in Figure 3. Because the age of diagnosis was later than expected, we analyzed
this variable in
n comparison to others. In general the more severely affected individuals
received a diagnosis at a younger age. This is further discussed in a later section.
Figure 3. Ages of TSC Diagnosis

Number of Women

30
25

Independent Women
Mean: 19.8 years 14.9
n=136

20
15

Dependent Women:
Mean: 6.6 years 10.1
n=39

10
5
0
0-1

"1-9"
9"

"10-19"

20-29

30-39

40-49

50-59

60-69

Age Ranges (years)
Family History
Of all the respondents, 73 (40.1%) indic
indicated
ated having another family member with TSC,
ranging from 34 women listing one affected family member to one respondent listing six
affected family members. The frequency of specific degrees of relation to the respondent is
presented in Table 11. By this an
analysis,
alysis, our sample appears to contain 76.9% of individuals
with no family history of TSC. This is higher than the expected 66 – 70% of individuals
expected to have a de novo mutation, but could also reflect less awareness or reporting of
affected family members.
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Table 11. Family History Involvement in Women With TSC
Independent
Women

Dependent
Women

Average number of affected relatives

n (%)
103 (73.6)
37 (88.1)
N=140
N=42
66 (47.1)
7 (17.5)
N=140
N=42
2.3 ± 1.7
1.75 ± 2.2

Affected Relative
Mother
Father

Number of Women
15
1
8
1

Sister
Brother
Daughter
Son
Grandmother
Grandfather
Aunt
Uncle
Cousin – Female
Cousin – Male
Niece
Other

16
14
29
25
3
4
5
0
7
3
8
6

Women with no family history (de novo)
Women reporting family history

1
1
2
0
1
1
1
1
1
0
0
0

Genetic Testing

Table 12. Genetic Testing Results in Women With TSC
Receiving Testing
Mutation testing results
N=93

n

(%)

TSC1
TSC2
No mutation identified
Other
Result Unknown

9
17
28
4
35

(9.7)
(18.3)
(30.1)
(4.3)
(37.6)
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Ninety-three (51.1%) women indicated they did have genetic testing, while 69 (37.9%) said
they did not; 13 (7.1%) did not know. Of those who did, 93 reported results presented in Table
12. Although over half of the women reported receiving genetic testing, over 37% of these did
not know the results of their test, providing less information on the frequency of mutations in
either TSC1 or TSC2.
Seizure History
Seizure history included age of onset and frequency of seizures, as well as past and
current medications used for seizure control and whether surgery was ever performed (Tables
13-16). Overall, 114 (62.6%) women indicated having a history of seizures, with an average
onset of 7.0 ± 10.8 years. The majority (59.1%) of women reported a frequency of seizures as
less than once a year. A lower frequency than would be expected in TSC reflects milder
disease in independent women. Thus the data is separated to show seizure history for
dependent and independent women, the former of which have a higher prevalence of
seizures. Fifteen women (13.2% of those with a seizure history) indicated having surgery for
their seizures.

Table 13. Seizure History in Women with TSC
Seizure History

Independent women

Dependent women

All women

Number reporting seizures
n (%)
Mean age of onset (years)
Range in age of onset
(years)

76 (54.3%)
N=140
9.3 ± 11.8

38 (90.5%)
N=42
2.5 ± 6.4

114 (62.6%)
N=182
7.0 ± 10.8

0 – 45

0 – 34

0 – 45

Frequency
n (%)
At least once a day
At least once a week, but not
daily
At least once a month, but not
weekly
At least once every six
months, but not every month
Less than once a year
Number reporting surgery
for seizures

Independent Women
N=69
5 (7.3)

Dependent Women
N=36
6 (16.7)

All Women
N=105
11 (10.5)

6 (8.7)

9 (25)

15 (14.3)

4 (5.8)

4 (11.10

8 (7.6)

8 (11.6)

1 (2.8)

9 (8.6)

46 (66.7)

16 (44.4)

62 (59.1)

10 (13.2)

5 (13.2)

15 (13.2)
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In addition to asking about what current and previous seizure medications women
used, we asked them to include the dosage, frequency, and an estimate of effectiveness on a
scale of 1 to 3. Women used the scale to note how effective they believed the medication(s) to
be; 1 “did not work well,” 2 “neutral,” “3 worked well.” Medication data is presented in Tables
14 -16b. The most common seizure medication in use by independent women was Keppra, at
an average dose of 1000 mg an average frequency of twice per day, taken for an average
length of 4 years, and rated an average effectiveness of 3. For dependent women, the most
frequently used current seizure medication was Depakote, with an average dosage of 250 mg
two times per day, an average length of 24 years, and average effectiveness of 3.

Table 14. Medication History in Women with Seizure History
Independent Women
N=69

Dependent Women
N=38

47 (68.1)

36 (94.7)

1.5 ± 0.9

1.7 ± 1.0

62 (89.9)

29 (76.3)

2.0 ± 1.6

3.1 ± 2.6

Reporting current medications
n (%)
Average number of medications
Reporting previous medications
n (%)
Average number of medications
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Table 15. Current Seizure Medications Reported by Women With TSC

Depakote
Diastat
Dilantin
Felbatol
Gabapentin
Keppra
Klonopin
Lamictal
Lorazepam
Neurontin
Phenobarbital
Tegretol
Topamax
Trileptal
Valium
Vimpat
VNS implant
Zonegran

Number
of
women
5
1
2
2
1
14
2
11
1
2
6
11
6
3
1
1
1
2

Median
dosage
(mg)
250
300
1000
0.75
150
60
300
150
600
-

Banzel
Clobazam
Depakote
Diastat
Dilantin
Felbatol
Keppra
Klonopin
Lamictal
Mysoline
Phenobarbital
Sabril
Tegretol
Topamax
Trileptal
Vimpat
Zonegran

2
1
12
2
2
2
4
3
4
1
4
3
10
3
6
2
2

250
300
1000
0.75
150
60
300
150
600
-

Name

Independent
women
N=47

Dependent
women
N=36

36

2/day
1.5/day
3/day
2/day
2.5/day
2/day
1/day
2/day
2/day
2/day
-

Median
years
taken
24
27.5
9
4
6.5
5
5.5
36
18
6
8
-

2/day
1.5/day
3/day
2/day
2.5/day
2/day
1/day
2/day
2/day
2/day
-

24
27.5
9
4
6.5
5
36
18
6
8
-

Median
frequency

Median
Effectiveness
3
2.5
2.5
3
3
2.5
2.5
3
3
2.5
3
2.5
2.5
3
3
2.5
3
3
2.5

Table 16a. Previous Seizure Medications Reported by Dependent Women With TSC

Name

Dependent
Women
N= 29

ACTH
Ativan
Clobazam
Clonazepam
Klonopin
Depakote
Dilantin
Felbatol
Gabitril
Keppra
Lamictal
Lyrica
Mellaril
Mysoline
Neurontin
Phenobarbital
Sabril
Tegretol
Topamax
Tranxene
Trileptal
Unknown
Valium
Zarontin
Zonegran

Number of
women
2
1
1
1
3
10
12
3
2
4
7
1
1
2
1
8
3
13
3
1
2
3
2
1
3
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Number years
taken
1
2
7
0.12
1.75
4.5
9
1.5
0.12
1
0.5
4
6
8
1.1
5
3
4

Average
Effectiveness
2
0
3
1
1.5
3
3
1
1
1
1
1
1.5
3
1
1
1
1
0.5
2
1

Table 176b. Previous Seizure Medications Reported by Independent Women With TSC

Name
ACTH
Carbatrol
Depakote
Diamox
Dilantin
Felbamate
Keppra
Klonopin
Independent
Lamictal
Women
Mogadon
N= 62
Mysoline
Neberil
Neurontin
Phenobarbital
Tegretol
Topamax
Trileptal
Unknown
Vigabatrin

Number of
women
2
3
12
1
33
1
3
1
4
1
2
1
8
24
21
3
2
2
1
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Number years
taken
0.5
9
5
1
6
1
2.5
5
1
-1
-1
8
5
2
0.25
-3

Average
Effectiveness
2
1.5
2
1
2
1
1
1
1
3
1
1
1
3
2
1
1
-3

Clinical Manifestations
The last two sections of the TSC portion of the questionnaire focused on the presence of
intellectual impairments, and specific clinical manifestations listed by affected organ. For each,
women were asked to report a current /prior existence of diagnosis/manifestation, and the age
at which they were diagnosed, where applicable.
By far, the most commonly reported neuropsychiatric diagnosis was depression, present in
72 (39.6%) women (Table 17). The finding is considered in light of rates of depression in
women, in individuals with genetic disease, and in individuals with other psychiatric
disturbances and is discussed later. We further analyzed this by combining depression with
other diagnoses (anxiety, OCD, bipolar disorder) into a sub-category of “mood disorders.” We
found a prior or current diagnosis of these mood disorders in 65 (47.8%) independent women,
and 22 (52.4%) dependent women, for total of 87 women (47.8%) in the sample. Further
analysis between women with a history of a “mood disorder” and those women without is
provided in Table 18.
Other common diagnoses were learning disabilities, intellectual disability , and ADHD. Less
common were OCD and Autism, and dyslexia. As with seizures, it is expected that dependent
women would be more severely affected by cognitive impairment; thus, the data for
neuropsychiatric manifestations of TSC is shown separately for dependent and independent
women.
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Table 187. Diagnosis of Neuropsychiatric Disorder in Women with TSC
n (%)
Independent women

Disorder /
Diagnosis

Current /
previous
n (%)

Learning
Disability
ADHD

Autism
MR
Dyslexia
OCD
Depression
Bipolar
Disorder
Other

Dependent women

Age Diagnosed (years)
Mean

Range

35 (25.9)
N=135

7.9 ± 5.3

2 – 20

9 (6.7)
N=134

12.9 ± 7.5

5 – 25

3 ± 1.4

2–4

3.3 ± 1.5

2–5

12.7 ± 4.6

10 – 18

21.4 ± 9.5

14 – 38

27 ± 10.6

13 – 46

33.2 ± 10.9

18 – 47

26.4 ± 12

11 – 45

3 (2.2)
N=134
4 (3.0)
N=133
8 (5.9)
N=135
8 (6.0)
N=134
59 (42.8)
N=138
5 (3.7)
N=134
16 (28.6)
N=56

Current /
previous
n (%)

Age Diagnosed (years)
Mean

Range

27 (64.3)
N=42

5 ± 4.9

0 – 20

8 (19.0)
N=42

4.4 ± 3.5

1 – 10

4 ± 5.4

1 – 16

3.2 ± 2.4

1 – 10

15 ± 7.1

10 – 20

13 ± 4.2

10 – 16

23.5 ± 9.6

10 – 35

23 ± 11.3

15 – 31

10.9 ± 8.5

1 – 25

9 (21.4)
N=42
25 (59.5)
N=42
2 (4.8)
N=42
6 (14.3)
N=42
13 (31.0)
N=42
4 (9.5)
N=42
9 (21.4)
N=42

Table 19. Women with Mood Disorders: Statistically Significant Findings
n (%)
Finding
Shortness of Breath with Exertion
Night Sweats
Hot Flashes

Mood Disorder
38 (43.7)
n=95
9 (28,1)
n=32
8 (25,0)
n=32
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No Mood Disorder
23 (24.1)
n=87
3 (7.1)
n=42
1 (2.4)
n=41

(p<0.005)
p value
0.022
0.038
0.009

To assess the severity of brain manifestations of TSC, we asked women to report a history
of SEGA, and any associated treatment. Twenty-two (12.5%) women indicated being
diagnosed with SEGA, while 44 (25.0%) reported they did not know. Of those who did, ten had
treatment, all of which was reported to be surgery; one woman indicated both surgery and
radiation.
Clinical manifestations of TSC are presented in Table 19 and are separated into
Dermatological, Renal, Pulmonary, and Cardiac categories. Specific manifestations are shown
in Tables 20 – 23 for each organ system.

Table 20. Overall Organ System Involvement in Women With TSC

Organ System

n (%)
Independent women
Dependent women

Dermatological
Renal
Pulmonary
Cardiac

133 (95.0)
N=140
80 (57.1)
N=140
67 (47.9)
N=140
38 (27.1)
N=140

42 (100.0)
N=42
30 (71.4)
N=42
18 (42.9)
N=42
16 (38.1)
N=42

Table 21. Dermatological Involvement in Women With TSC

Manifestation
Angiofibromas
Hypopigmented Macules
Finger / Toe Nail Tumors

n (%)
Independent women
Dependent women
115 (82.1)
N=140
124 (88.6)
N=140
84 (60.0)
N=140
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39 (92.9)
N=42
37 (88.1)
N=42
25 (59.5)
N=42

Table 22. Renal Involvement in Women With TSC
n (%)
Manifestation

Renal Cysts
Angiomyolipoma
Renal Cancer

Independent women

Dependent women

63 (45.0)
N=140
63 (48.1)
N=140
3 (2.1)
N=140

27 (64.3)
N=42
22 (52.4)
N=42
3 (7.1)
N=42

Table 23. Pulmonary Involvement in Women With TSC

Manifestation
Pulmonary Cyst
LAM
Shortness of Breath
with Exertion

n (%)
Independent women
Dependent women
30 (21.4)
N=140
35 (25.0)
N=140
47 (33.6)
N=140

8 (19.1)
N=42
8 (19.1)
N=42
14 (33.3)
N=42

Table 24. Cardiac Involvement in Women With TSC

Manifestation
Rhabdomyomas
Irregular Heartbeat

n (%)
Independent women
Dependent women
10 (7.1)
N=140
33 (23.6)
N=

42

10 (23.8)
N=42
13 (31.0)
N=42

POF
The reproductive histories of all women were looked at in detail. Women who had irregular
cycles early in their lives that persisted were considered to have a different reproductive
dysfunction. However, women who had regular cycles most of their life but later changed to
irregular cycles later in their reproductive lives, particularly after age 35 were considered to
have possible POF as this is a common pattern in women have been documented with this
diagnosis. This pattern was observed in 18 women; 16 independent women, and two
dependent women. The group was further refined to exclude those women whose other
information that was inconsistent or incomplete. This resulted in a total of eight women who
were deemed to have a “possible” diagnosis of POF. One of these women was dependent
(discussed later), and the remaining seven were independent.
Of note, four women out of the total 182 participants reported receiving a diagnosis of
POF, but two were excluded due to contradictory and/or insufficient information. One woman
indicated receiving a diagnosis of POF at age 45, which would not be clinically accurate. She
also reported a diagnosis of PCOS at age 42, a hysterectomy at age 32, and an oophorectomy
at age 42. This history suggests she had other reproductive problems but is not consistent with
a decline in ovarian reserve observed in POF. The second woman reported a diagnosis of
POF at age 33. Her entire menstrual history was lacking with the exception of reported
irregular periods without oral contraceptive use at age 40. Thus, we cannot assess her
menstrual history for a progression from regular periods to irregular periods. Furthermore, this
individual reported a miscarriage at age 40. The other two women reporting a diagnosis of
POF are included in the group of seven women. One of these women reported a diagnosis of
POF at age 39, and also reported a history of anorexia, a disease in which menstrual
abnormalities are common. She did not, however, indicate an age of this diagnosis. The
second women reported a diagnosis of POF at age 40. She indicated receiving radiation
therapy at an unspecified location and age. This woman had no seizure history, no known
history of SEGA, and therefore was unlikely to have received radiation to the head for TSC
management. We cannot, however, exclude the possibility of pituitary failure due to disruption
of the pituitary hypothalamic ovarian axis. In addition, her uterus and ovaries remained intact,
making pelvic radiation – a more direct cause of POF - less likely.
Analysis was performed on the seven independent with presumptive POF. Because of the
global differences between independent and dependent women in this study, further analysis
was performed in comparison to independent women only. A statistical comparison of all
variables was made between these women and 110 independent women not determined to
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have possible POF over the age of 30. in an effort to use a population both similar to the
seven women being studied, and to a typical presentation of POF itself. Information for the one
dependent woman with possible POF is summarized in Appendix B.
The data for women with possible POF is presented in Tables 24 - 44. There were four
statistically significant findings in the comparison between women with possible POF and
independent women over the age of 30 without possible POF. These include: Lower frequency
of hypopigmented macules in women with possible POF (Table 41); A higher frequency of
reported high blood pressure in women with possible POF (Table 28); Report of blood tests
revealing a menopausal state in women with possible POF as compared to independent
women without possible POF between the ages of 30 and 40 (Table 29); A higher frequency of
reported shortness of breath upon exertion in women with possible POF (Table 45).

44

Table 25. Demographic Information: Independent Women With Possible POF and
Independent Women Without Possible POF over the age of 30

Median:
Range:

Possible
POF
n (% of 7)

n (% of 110)

Age
44 years
18 – 77 years

35 years
18 – 68 years

Possible
POF
n (% of 7)

Non-POF

Single
Married
Divorced
Widowed

Marital Status
1 (14.3)
4 (57.1)
1 (14.3)
1 (14.3)

Non-POF
n (% of 110)

20 (18.2)
71 (64.6)
15 (13.6)
4 (3.6)

Employment Status
Unemployed
1 (14.3)
23 (20.9)
Part-time
0
13 (11.8)
Full-time
2 (28.6)
50 (45.5)
Student
0
1 (0.9)
Disabled
1 (14.3)
9 (8.2)
Retired
3 (42.9)
7 (6.4)
Other
0
7 (6.4)

Annual Household Income
< $10,000
0
6 (5.5)
$10,000 – 24,000
1 (14.3)
10 (9.1)
$25,000 – 49,000
0
24 (21.8)
$50,000 -74,999
0
13 (11.8)
$75,000-99,999
3 (42.9)
19 (17.3)
> $100,000
0
11 (10.0)
Decline / blank
3
27 (24.5)

Household Status
1 (14.3)
20 (18.2)

Highest Education Level
Under 12th grade
0
2 (1.9)
th
Completed 12
4 (57.1)
20 (18.2)
grade
Some college
1 (14.3)
36 (32.7)
Bachelor / Master
2 (28.6)
52 (47.3)
degree

Alone
With family

5 (71.4)

63 (57.3)

With S/O
Assisted
living

1 (14.3)

27 (24.6)

0

0

Ethnicity
6 (85.7)

102 (92.7)

Caucasian
AfricanAmerican
Hispanic
Asian
Other

1 (14.3)

2 (1.8)

0
0
0

1 (0.9)
1 (0.9)
4 (3.6)

The majority of the seven women with possible POF were Caucasian, married, working
full-time or retired, and had completed high school and/or some college (Table 24). Though
they all displayed menstrual irregularity of consistently regular cycles to consistently irregular
cycles, the average age of menarche (12.7 years) was comparable to both the other women
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sampled and the general population (Table 25 and Figure 4). This suggests intact ovarian
function at the start of puberty. Rates of pregnancy were also similar to that of the entire study
population, and women on average had 1.
1.6 children, with an average age of first pregnancy of
21.8 years. One of the seven women reported miscarriage at age 31, one reported preterm
birth, and 0 reported a history of voluntary termination (Tables 26 and 27).

Table 26. Menstrual History

Menstrual category

No POF
N=110
n (%)

Possible POF
N=7
n (%)

Always regular
Always irregular
Regular to irregular
Alternating regularity
Uninformative

59 (53.6)
15 (13.6)
6 (5.5)
12 (10.9)
18 (16.4)

0
0
7 (100)
0
0

Figure 4. Age of Menarche
35

Number of Women

30
Possible POF
Mean: 12.7 years 1.5

25
20

No POF
Mean: 12.4 years 1.6

15
10
5
0
7

8

9

10

11

12

13

14

Age (years)
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15

16

17

18

Table 27. Pregnancy

Women pregnant at any time
Average number of live births
Average age at first birth
Number of women who had a preterm
birth
Women who had a voluntary termination

Non POF

Possible POF

75 (68.2 %)
N=110
1.8 ± 1.6
25.6 ± 5.7
5 (8.4%)
N=68
15 (20.0%)
N=75

5 (71.4%)
N=7
1.6 ± 0.5
21.8 ± 2.9
1 (20%)
N=5
0

Table 28. Miscarriage History
Non POF
32 (43.2%)
N=74
28.6 ± 6.2
1.7 ± 1.1

Women who had a miscarriage
Average age of miscarriage
Average number of miscarriages

Possible POF
1 (20.0%)
N=5
31
1

The most commonly reported current or previous reproductive symptoms were hot flashes,
night sweats, high blood pressure, and weight gain, each present in over half of women with
possible POF (Table 28). Two women indicated receiving a blood test indicating a menopausal
state (Table 29). Three had a hysterectomy, and two reported oophorectomy. These occurred
at an average age of 43.5 and 44 years, respectively (Table 30). Of the reproductive disorders,
diagnoses of infertility, amenorrhea, and autoimmune disease were reported in three women
with possible POF; frequencies of all reproductive disorders are provided in Table 31. There
were, on average, 4 medications taken by women with possible POF. Categories and
frequencies of medications are shown in Table 32.
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Table 29. Reproductive Symptoms

Symptom

Non POF
Under the Age of 40
Current or
Average
previous
duration
n (%)
(years)
4 (15.4)
N=26
8 (30.8)
N=26
6 (23.1)
N=26
8 (30.8)
N=26
6 (23.1)
N=26

12.5 ± 10.7

11 (42.3)
N=26

N/A

Hot Flashes
Night Sweats
Body Hair
High Blood Pressure*
Milky breast discharge
excluding breastfeeding
Weight gain over 25
pounds, excluding
pregnancy
* p=0.027

4.5 ± 4.8
1.3 ± 0.5

3±0
1.1 ±1.3

POF
Current or
previous
n (%)
5 (83.3)
N=6
5 (83.3)
N=6
0
N=6
5 (83.3)
N=6
1 (16.7)
N=6

Unknown

4 (66.7)
N=6

N/A

Table 30. Reproductive Blood Tests

Blood Test Indicating:
Menopausal State*
Thyroid Disease
Elevated Testosterone
Levels
*p = 0.009

Non POF
Under the Age of 40
n (%)
0
N=12
3 (25)
N=12
1 (8.3)
N=12
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Average
duration
(years)

Possible POF
n (%)
2 (28.6)
N=7
1 (14.3)
N=7
0
N=7

Unknown
Unknown

Unknown
Unknown

Table 31. Surgical History in Independent Women with TSC

Surgery
Hysterectomy
Oophorectomy
Radiation therapy
Chemotherapy

Non POF
Average
N (%)
Age
31 (28.7)
35.4 ± 9.8
N=108
17 (16.2)
41.2 ± 7.7
N=105
2 (1.9)
Unknown
N=106
1 (1.0)
45
N=106

Possible POF
Average
N (%)
Age
3 (57.1)
43.5 ± 7.8
N=7
2 (28.6)
44 ± 7.1
N=7
1 (14.3)
Unknown
N=7 *
0
N/A
N=7

*site of radiation unknown

Table 32. Reproductive Diagnoses

Diagnosis

POF
PCOS
Amenorrhea
Infertility

Non POF
Average Age
N (%)
Diagnosed
2* (1.9)
N=108
10 (9.4)
N=107
9 (8.4)
N=107
12 (11.1)
N=108

Possible POF
Average Age
N (%)
Diagnosed

39 ± 8.5

2 (33.3)
N=6

39.5 ± 0.71

34.7 ± 14.2

0

N/A

30.6 ± 11.5
31.2 ± 6.3

Anorexia

4 (3.7)
N=108

20.3 ± 1.5

Addison disease

1 (0.9)
N=107
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Autoimmune Disease

13 (12.2)
N=107

36.6 ± 15.0

1 (16.7)
N=6
1 (16.7)
N=6
1
(16.7)
N=6
0
0

Unknown
28
N/A
N/A
Unknown

* Excluded from possible POF group due to inconsistent/contradictory information
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Table 33. Current Medications (Non-seizure) in Independent Women with TSC
Type of Medicine
Number of women reporting medication
Average number of medications used

Non-POF
87 (79.8%)
5.2 ± 4.2

Possible POF
4 (57.1%)
4

Analgesic
Anti-histamine
Anti-microbial
Asthma-related
Bisphosphonate
Contraceptives/HRT
High Blood Pressure
Multivitamin
Other
PPI/GERD
Psychotropic
Statin
Steroids
Supplement
Thyroid hormone

36
18
8
21
8
20
26
35
40
12
43
25
14
104
21

1
0
2
0
0
1
1
0
4
2
2
2
1
0
0

Overall, our data for the entire study population indicated a later age of TSC diagnosis, a
higher prevalence of mood disorders, and a less severe course of TSC disease. The seven
independent women with possible POF did not appear significantly different in regard to their
clinical severity. The average age of TSC diagnosis was 23.7 years (Figure 4). A family history
of TSC was reported by six of the women, indicating a lower rate of apparent de novo disease.
Frequencies of affected relatives with respect to the survey participants are shown in Table 33.
Genetic testing results are shown in Table 34. Three women with possible POF reported
receiving testing, but two did not know the result. Unknown mutation testing results was also
seen in the entire sample population, providing little data to utilize genotype in hypothesizing a
correlation with women’s’ reproductive history.
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Figure 5. Ages of TSC Diagnosis
Number of Women

30
25
20

Non POF:
Mean: 22.6 years

14.5

Possible POF:
Mean: 23.7 years

12.6

15
10
5
0
0 -9

10 to 19

20 -29

30 -39

40- 49

50 59
50-

60- 69

Age Ranges (years)

Table 34.. Family History Reported in Women with TSC
Non POF

Possible POF
n (%)

Average number of affected relatives
Mother
Father
Sister
Brother
Daughter
Son
Grandmother
Grandfather
Aunt
Uncle
Cousin – Female
Cousin – Male
Niece
Nephew
Other

51 (46.8)
N=109
2.33
7
8
14
10
28
21
2
3
3
4
4
1
8
2
4

6 (85.7)
N=87
1.33
2
0
1
1
0
2
0
0
0
0
0
0
0
0
1

Women
omen with unknown family history
Women
omen with no family history ((de novo)

16 (14.7%)
42 (38.5%)

1 (14.3%)
0

Women reporting family history
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Table 35. Genetic Testing Results in Independent Women with TSC
n (%)
Women reporting genetic
Testing

Non POF
61 (55.5)
N=110

Possible POF
3 (42.9)
N=7

TSC1
TSC2
No mutation identified
Other
Don’t Know result

6 (9.8)
10 (16.4)
20 (32.8)
2 (3.3)
23 (37.7)

0
1 (33.3)
0
0
2 (66.7)

Data on seizure history, age of onset, and frequency is shown in Table 35. Four of the
seven women reported a history of seizures, with a mean age of onset of two and a half years.
All of these women reported a seizure frequency of less than once a year. One women
currently uses seizure medication, and the four mentioned above provided information on
previous seizure medication use. Data on seizure medication are presented in Tables 36-38.
The possible relationship between seizure history, anti-epileptic drug use, and menstrual
irregularities is provided in the discussion section.

Table 36. Seizure History in Independent Women with TSC
Seizure History
Number reporting seizures
Mean age of onset (years)
Range in age of onset (years)

Non POF
55 (50.0%)
N=110
11.6 ± 12.7
0.3 – 45

Frequency n (%)
At least once a day
At least once a week, but not
daily
At least once a month, but not
weekly
At least once every six months,
but not every month
Less than once a year
Number reporting surgery for
seizures

N=49
4 (8.2)
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Possible POF
4 (57.1%)
N=110
2.5 ± 2.4
0–5
N=4
0

4 (8.2)

0

3 (6.1)

0

8 (16.3)

0

30 (61.2)

4 (100)

5 (9.1)

0

Table 38. Seizure Medication History in Independent Women with TSC
Non POF

Possible POF

N
(% of women with seizure history)

Average number of medications

30 (27.3)
N=110
1.6 ± 0.9

1 (25)
N=4
1

Reporting previous seizure medications
Average number of medications

41 (37.3)
1.8 ± 1.3

4 (100)
1.4 ± 0.55

Reporting current seizure medications

Table 37. Current Seizure Medications in Independent Women with TSC

Non POF
N=30

Depakote
Dilantin
Felbatol
Gabapentin
Keppra
Klonopin
Lamictal
Lorazepam
Phenobarbital
Tegretol
Topamax
Trileptal
Valium
Zonegran

Number
of
women
4
2
1
1
9
2
7
1
6
8
4
1
1
2

Median
dosage
(mg)
375
300
600
600
750
.75
300
1
60
350
175
1800
5
75

Median
frequency
(X / day)
3
1.5
4
2
2
2.5
2
1
1
2
2
1
1
2

Median
years
taken
19
27.5
15
4
3.5
6.5
4
13
36
20
2
9
6
4

Possible POF
N=1

Neurontin

1

300

3

10

Name

53

Median
Effectiveness
2.5
2.5
2
2
3
3
3
1
2.5
3
2
3
3
2
3

Table 39. Previous Seizure Medications in Independent Women with TSC

Non POF
N= 40

ACTH
Carbimazole
Cortizone
Depakote
Dilantin
Keppra
Lamictal
Mogadon
Mysoline
Neberil
Neurontin
Phenobarbital
Tegretol
Topamax
Trileptal
Unknown

Number of
women
1
1
1
7
24
1
1
1
1
1
6
15
11
1
1
2

Number years
taken
1
6
1
1
3.75
2
1
0.5
1
6.5
5.5
-

Average
Effectiveness
3
2
3
1.5
2.5
1
1
3
1
1
1
3
2
-

Possible
POF
N=4

Dilantin
Phenobarbital
Tegretol

2
1
1

14
2
-

2
2
1

Name

Depression was the most common psychiatric manifestations of TSC in these seven
women, present in five women (Table 39), with an average duration of 27 years. This adds to
the high numbers of depression observed in the entire study sample.
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Table 40. Diagnosis of Neuropsychiatric Disorder in Independent Women with TSC

Non POF Independent Women

Disorder
Learning
Disability
ADHD

Current or
previous
diagnosis
N (%)
25 (23.4)
N=107
7 (6.6)
N=106

Possible POF Independent Women

Average age
diagnosed
(years)
8.4 ± 4.6

Current or
previous
diagnosis
N (%)
1 (16.7)
N=6

Average age
diagnosed
(years)
18

15.6 ± 7.2

0

-

Autism

0

-

0

-

MR

0
6 (5.6)
N=107
6 (5.7)
N=106
49 (45.0)
N=109
5 (4.7)
N=106
14 (28.6)
N=49

-

0
1 (16.7)
N=6

-

Dyslexia
OCD
Depression
Bipolar
Disorder
Other

14 ± 5.7

Unknown

23.3 ± 9.9

0

-

28.2 ± 10.8

5 (71.4)
N=7

27

33.2 ± 10.9

0

-

28.7 ± 11.9

1 (33.3)
N=3

14

Lastly, the manifestations of specific organ systems affected by TSC are presented in Tables
40 through 44. Aside from the differences in the aforementioned dermatological manifestations
a comparable number of women indicated the presence of renal, pulmonary, and cardiac
issues in both groups.
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Table 41. Overall Organ System Involvement in Independent Women
with TSC
n (%)
Non POF
N=110

Possible POF
N=7

Dermatological

106 (96.4)

5 (71.4)

Renal
Pulmonary
Cardiac

65 (59.1)
58 (52.7)
28 (25.5)

4 (57.1)
4 (57.1)
4 (57.1)

Organ System

Table 42. Dermatological Involvement in Independent Women with TSC

Manifestation

Angiofibromas

n (%)
Non POF
N=110

Possible POF
N=7

91 (82.7)

4 (57.1)

Hypopigmented Macules*
97 (88.2)
5 (74.1)
Fingernail / Toenail
68 (61.8)
3 (42.9)
Tumors
* This finding was statistically significant, with a p value of 0.021

Table 43. Renal Involvement in Independent Women with TSC

Manifestation
Renal Cysts
Angiomyolipoma
Renal Cancer

n (%)
Non-POF
N=110

Possible POF
N=7

51 (46.4)
52 (47.7)
3 (2.7)

4 (57.1)
2 (28.6)
0
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Table 44. Pulmonary Involvement in Independent Women with TSC
n (%)
Manifestation

Non-POF
N=110

Possible POF
N=7

Pulmonary Cyst

26 (23.6)

2 (28.6)

LAM

29 (26.4)

3 (42.9)

Shortness of Breath with Exertion*

41 (37.3)

5 (71.3)

* p = 0.024

Table 45. Cardiac Involvement in Independent Women with TSC
n (%)
Non-POF
N=110

Possible POF
N=7

Rhabdomyomas

4 (3.6)

1 (14.3)

Irregular Heartbeat

27 (24.5)

4 (57.1)

Manifestation

Table 46. Women with Possible POF: Statistically Significant Findings
n (%)
Finding

Possible POF
5 (71.3)
N=7
5 (83.3)
N=6 *

(p<0.005)

Non-POF
p value
41 (37.3)
Shortness of Breath with Exertion
0.024
N=110
3 (25)
High Blood Pressure
0.024
N=12
2 (28.6)
Blood Test Indicating Menopausal State
0*
0.009
N=7
5 (74.1)
97 (88.2)
Hypopigmented Macules
0.021
N=110
N=7
* Comparison was limited to independent, non-POF women between the ages of 30 and 40
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Overall, our data for women with possible POF is based on clinical refinement of selfreported menstrual histories and trends. The limited sample size makes a comparison to
women whose histories were not suggestive of POF difficult. However, the small differences
noted and other observations in the overall population do warrant further discussion.
Discussion
This study was designed to estimate the prevalence of premature ovarian failure in a
sample of women affected with TSC. It is the first study to highlight significant menstrual
dysfunction in women with TSC. The hypothesis was based on evidence from conditional
knock-out mice models that indicated the importance of the TSC genes and mTORC
regulation in murine ovarian function. The aim of the study was to determine what, if any,
association may exist between the development of POF and TSC in women. Questionnaires
were sent to 1000 adult female members of the Tuberous Sclerosis Alliance, a national
support group, providing self-reported data on demographics, reproductive history, and TSC
manifestations. A total of 182 qualifying surveys were informative and used in the analysis,
and 18 surveys were excluded due to insufficient information or underage respondents.
Demographic analysis demonstrated a high socio-economic status for this group of 182
women. TSC clinical data suggested milder disease than typically observed in TSC patients.
As variable expressivity is a well-established feature of TSC, we did not anticipate that milder
disease would underestimate the presence of reproductive issues in these women. In fact,
given this caveat, our study would be predicted to underestimate reproductive problems in the
overall TSC female population.
POF
Our data suggest that there is an increase in the prevalence of POF in women with TSC
compared to the general population. Analysis of 182 women categorized 9 with “possible POF”
(4.95%). Two of these women reported receiving a diagnosis of POF. The selection of women
from which to consider the possibility of POF was created through application of stringent
reproductive and menstrual criteria. Since the diagnosis of POF involves the cessation of
menses before the age of 40, self-reported data of menstrual history for time frames between
18 and 40 were used as an initial filter to categorize women. The natural history of POF
typically involves regular menses, followed by irregular cycles, before the complete cessation
of menses. Therefore, women considered for a categorization of “possible POF” were
identified by menstrual trends indicating consistently regular cyclicity progressing to
consistently irregular cyclicity as previously defined in the Methods. Our refinement resulted in
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a sample of 18 women. Of these, nine were excluded upon further analysis of clinical features,
as their histories were consistent with other reproductive disorders, such as PCOS. The
remaining eight women included seven independent respondents and one dependent
respondent. Independent women were those that completed the questionnaire themselves,
whereas dependent women were those for whom a questionnaire was completed by a
caretaker, suggesting more severe TSC manifestation or cognitive disability. Because our
initial comparisons of independent and dependent women in the entire sample of women
revealed differences between these groups, the dependent woman was excluded from further
analysis of the group with possible POF. Furthermore, it is less likely that women would
present with POF in their 20s, so comparison between the seven independent women with
possible POF was limited to independent women over the age of 30 years. Choosing this age
constraint allowed for a more direct comparison of groups.
Few studies have empirically assessed the prevalence of POF in the general population.
The literature primarily quotes an estimate of 1% that comes from a longitudinal study from
1983 [Coulam]. Previously, estimates of POF came from cohort studies analyzing specific and
narrow age ranges. Coulam, et al. followed a cohort of 1858 women and found an incidence of
0.9%. They also reported that the risk to develop POF increases from 0.1% at age 30 to 1% by
40 years of age; a ten-fold increase over a ten year period. Thus, our finding of possible POF
in nine (4%) of women studied is a significant finding, particularly as only two of these women
reported receiving a diagnosis of POF. As discussed earlier, there is often a delay in the
diagnosis of POF, especially for women who are not struggling with conception. Other causes
for delayed diagnosis are varied symptomatology and other etiologies for isolated menstrual
irregularity. In women with a genetic condition that affects multiple organ systems, attention to
additional symptoms or medical problems may be misconstrued as related to TSC or
overlooked entirely. No studies have previously attempted to assess if there is an association
between TSC and menstrual irregularities such as POF.
Because we were not able to obtain medical data from women, we do not know if the
women with possible POF would have had elevations in FSH levels, necessary for a clinical
diagnosis. Thus our results fit with a broader possibility of premature ovarian insufficiency, or
POI, as was introduced earlier. This term encompasses declining ovarian reserve, which we
observed in analyzing women’s menstrual trends. The distinction is an important one, as we
lack clinical data to confirm diagnoses in these women, and the accuracy of “insufficiency”
better reflects a condition marked by reversibility and many unknowns.
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Analysis of women with possible POF was performed by comparing all variables for
significant associations. There was no statistically significant association between women with
or without possible POF with respect to age, demographic information, BMI, medication use,
seizure history, age at menarche, number of pregnancies or miscarriages, genetic testing
results, neuropsychiatric diagnoses, or TSC-related manifestations in cortical, pulmonary,
cardiac, or renal systems. The only statistically significant findings among these women in
comparison to the independent women without possible POF were related to reproductive
symptoms, report of receiving a blood testing indicating a menopausal state, and the presence
of facial angiofibromas, which were present in a smaller percentage (57.1%) of women with
possible POF compared to those without POF (82.6%). These findings could represent a true
association, or may be due to limitations of a small sample size or statistical chance. High
blood pressure and shortness of breath are both prevalent in the general population,
particularly in women at older ages. It may be expected that women experiencing menstrual
irregularity would have a blood test indicating a menopausal state, which may not necessarily
lead to a diagnosis of POF. As for the dermatological finding, additional manifestations of
these women were consistent with the rest of the sample, making it more likely that these
women were at increased risk for POF due to specific manifestations of TSC. The absence of
significant differences between women is consistent with the theoretical possibility that TSC
can manifest in any organ system, and does not suggest an increased likelihood in women
with more severe TSC disease from our specific sample. There was little data on genetic
testing results to uncover genotype/phenotype correlations, and thus further exploration of
reproductive issues in women with TSC would be useful in conjunction with molecular
information. It is noteworthy that there were no differences between the POF in mice with a
Tsc1 specific ovarian deletion compared to Tsc2 [Adhikari, 2010]. Other reproductive
problems revealed in these women suggest implications for ovarian function from mutations in
the TSC genes and warrant further study.
Additional data about reproductive history were considered in the eight women with
possible POF. Two women reported receiving radiation therapy, though we do not know the
ages when the treatment occurred. One woman indicated the therapy was for SEGA
treatment, while the other did not indicate a location. Radiation to the brain could disrupt the
hypothalamic-pituitary-ovarian axis, indirectly disrupting ovarian function. Alternatively, it is
known that pelvic irradiation can lead to POF, and shows an age and dose-dependent effect
[Nippita]. From the information given we cannot exclude either possibility for these
respondents, nor can we discern the likely effects of radiation on menstrual function without
knowing the ages when therapy occurred. Next, one woman did indicate a diagnosis of
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anorexia from the list of reproductive disorders. Anorexia is a known contributor to menstrual
irregularity, but the respondent did not specify an age at which the diagnosis of anorexia
occurred, negating a clear interpretation of any potential effects on the menstrual history.
Anorexia is more common in adolescence (ages 14-18), though recent evidence suggests it
may also be common among older women [American Psychiatric Association; Parker-Pope].
The study participant was 57 at the time the survey was completed, and her menstrual
irregularity began at age 37, though she did report use of oral contraceptives between the
ages of 21 and 30. She has symptoms of high blood pressure, takes Metformin, and has a
BMI over 32; thus it is unlikely her diagnosis of anorexia was recent given her history. Without
further information, we cannot depend on the respondent’s history of anorexia alone as a route
to menstrual irregularity. Report of additional reproductive problems varied across the 8
women but did include reproductive symptoms of night sweats and hot flashes, infertility,
and/or blood tests indicating a menopausal state. These would be consistent with a diagnosis
of POF, as women with POF experience perimenopausal symptoms at an earlier age than is
expected, and may be evaluated for reproductive dysfunction by infertility specialists or as they
near the age of menopause. Our reproductive and menstrual data indicate the criteria used for
considering women for POF are reliable, as most women with a consistent menstrual history
lacked contradictory information and instead contributed additional characteristics pointing to a
possibility of POF
Lastly, we analyzed if there were associations between POF and a history of seizures, as
well as current /previous seizure medications. Reproductive endocrine disorders and infertility
are more common among women with epilepsy than the general population, observations that
have been attributed to both epilepsy itself and the use of anti-epileptic drugs (AED)s. for
treatment [Isojarvi]. Epilepsy may directly affect reproductive function through disrupted
regulation of hypothalamic hormone release [Pimentel]. Additionally, many women with
epilepsy have catamenial seizures, presenting during menses and menopause when the
levels of steroid ovarian hormones change. The risk from AEDs is thought to originate from
their pharmacological induction of liver enzymes that gradually decrease the bioactivity of
ovarian hormones and androgens [Isojarvi]. Additionally, valproic acid has been reported to
have a possible effect on fertility, while limited data exists for the effects of gabapentin and
lamotrigine on reproductive function or fertility [Kaplan 2004].
We assessed if the use of AED or seizure history could be a possible explanation for the
etiology of possible POF in the sample of eight women. Two women reported use of current
seizure medications. These were lamotrigine, topirimate, and gabapentin. The two former
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medications were reported as current from one woman and were used for 16 years. The time
frame when the study participant reported an onset of irregularity is that immediately following
the start of her medication use. She also had the highest frequency of seizures of the women
with possible POF, occurring no greater than twice per month. Current use of gabapentin was
reported by one woman, for ten year duration. She reported the onset of menstrual irregularity
at age 38, approximately three years following the first use of this medication; she also
reported her last seizure occurred at age 28. Previous seizure medication use was reported for
five of the eight women with possible POF, and included phenytoin, valproic acid,
phenobarbital, and carbamazepine. None of these medications were used more than 14 years,
and the majority were ceased at least ten years prior to the onset of menstrual irregularity. We
cannot completely exclude the possibility that these medications had an effect on the
menstrual function of these women. However, there were also three women in the group with
possible POF that reported no history of seizures, and three women who reported an early
childhood onset of seizures and cessation of AED use several years prior to the onset of
menstrual irregularity. Our data suggest that neither seizures nor seizure medications alone
would be sufficient to account for the onset of POF in all women.
There were nine women who were excluded upon further refinement of the group showing
a history of menstrual regularity to irregularity. Clinical guidance from a reproductive
endocrinologist suggested other reproductive disorders in these women, including PCOS (one
subject reported a diagnosis of PCOS). We also found that overall, 31% of women with TSC
experienced some sort of menstrual irregularity. A number of women in the entire sample
reported a diagnosis of amenorrhea and infertility, mostly diagnosed by gynecologists and
infertility specialists. But a greater number with various forms of menstrual irregularities did not
report a diagnosis of any reproductive disorder. Furthermore, only a handful of these women
indicated having a blood test showing a menopausal state, thyroid disease, or elevated
testosterone levels. Overall our data suggest there is a lack of awareness of reproductive
issues in women with TSC. In light of missing data and an absence of medical chart review, it
is likely we have underestimated reproductive dysfunction in general and POF in particular for
the TSC population studied. Thus, thorough evaluation and attention to menstrual history, as
well as proper hormonal assessment of women with TSC is indicated, and further research will
aid in determining specific risk factors and characteristics of this issue.
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Additional Findings from the entire sample of women
Reproductive History
Although not originally intended as part of the study design, several other findings are
notable. The age of menarche in our sample was consistent with the national average (12.3
years), and points to intact menstrual functioning at the onset of menses [Anderson]. In
general, it is not uncommon for young women to display pubertal irregularities of abnormal
uterine bleeding during the initial 19 months of menstruation, typically reported with
anovulatory cycles due to an immature hypothalamic-pituitary-ovarian axis [Lemarchandberaud]. The duration of time that it takes to establish regular ovulatory cycles may to be
related to age at the time of menarche, and in most girls who begin menses between the ages
of 12 and 13, 50% of cycles are ovulatory by three years [Apter]. As the women in our survey
had an average age of menarche of 12, with a 75th percentile of 13, it would be expected that
any pubertal irregularities would normalize by the age at which data collection began, 16
years. Thus, irregularities in the first time frame surveyed (16-20 years) were not considered to
be due to pubertal irregularity and were instead counted as irregular. Initial normal
menstruation is consistent with a gradual progression to later development of POF.
Another metric for reproductive health is a history of pregnancy and miscarriage. We
found that 41.8% of women who reported ever being pregnant experienced a miscarriage,
higher than observed in the general population. The approximate distribution of miscarriage
rate estimates in the general population varies with maternal age; below 35 years, it is
estimated that women have a 15% risk to experience miscarriage; between 35-39 years, a 2025% risk; between 40-42 years, 35% risk, and over 42 years, a 50% risk [American Pregnancy
Association]. We also observed that the average age when these miscarriages took place in
our sample (28.5 years) was younger than the above ranges. A higher miscarriage rate at
younger ages may point to separate or additive effects related distinctly to TSC and not seen
in the general population. Lastly, 50% of the women who experienced miscarriage had a
menstrual history of always regular cycles, suggesting that menstrual irregularity alone is not a
sufficient predictor of miscarriage risk in women with TSC. Furthermore, as dependent women
generally became pregnant less often, we have limited data to assess whether severity of TSC
symptoms might play any role in the risk for miscarriage. Of 33 women reporting miscarriage,
17 (42.5%) also reported a history of seizures, while 16 (45.7%) reported no history of
seizures. Studies of pregnancy women with epilepsy have not observed significantly elevated
rates of fetal loss, though it does occur. Similar to the effects of epilepsy on menstrual
functioning previously discussed, it is difficult to differentiate between risks from seizures and
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AED use [Kaplan 2007]. A prospective study of pregnant women with epilepsy from 1994
observed 21% rate of fetal loss in a group of 119 women receiving AEDs, and a 12.2% rate of
fetal loss in 106 women not receiving medication [Steegers-Theunissen]. The elevated rates of
miscarriage at young ages suggest a distinct finding for women with TSC, for whom there is
little information on predictive factors or breadth of this issue.
Of the reproductive diagnoses reported and menstrual histories consistent with specific
reproductive dysfunction, PCOS was self-reported in 11 (6.04%) of the 182 women. We also
identified four women whose information was more consistent with that seen in PCOS from
our initial group of 18 women with a menstrual history of regular. PCOS is among the most
common menstrual irregularities in women today, with an estimated prevalence between 6 and
8% [Knochenhauer]. Risk factors and/or associations include infertility, insulin resistance,
diabetes mellitus, and family history [Allen; Hartz; Conn; Legro]. Of note, studies also indicate
the use of valproic acid to be associated with PCOS, and the drug may increase androgen
biosynthesis in theca cells [Bilo; Nelson-DeGrave]. Many healthcare providers monitor the
length of the menstrual cycles in women with epilepsy after commencement of treatment with
valproate [Isojarvi; Kaplan 2004]. A total of 14 women reported current use of valproate, and of
these, one indicated a diagnosis of PCOS, at age 45. Twenty-one women reported previous
use of valproate, one of whom indicated a diagnosis of PCOS at age 48.
Another common cause of menstrual irregularity, particularly oligomenorrhea and
menorrhagia, is hypothyroidism. A study reported such irregularities in approximately 23.4% of
women with hypothyroidism [Krassas]. The prevalence of overt hypothyroidism may vary from
0.1 to 2 percent in the population, while subclinical hypothyroidism is higher, ranging from four
to ten percent of adults, and is 5-8 times more common in women [Tunbridge; Kajantie]. We
observed 43 women (24.0%) reporting a blood tests indicating thyroid disease. Of the group of
18 women progressing from regular to irregular periods, four reported receiving a blood test
indicating thyroid disease, and one of these women is included in our group of possible POF.
Of the women with alternating cycles, six indicated thyroid disease, one of whom specified a
diagnosis of Hashimoto thyroiditis. Lastly, six of the 24 women whose menstrual history was
consistently irregular indicated thyroid abnormalities. Though we do not know the specific type
of thyroid disease we did observe menstrual abnormalities in approximately half of the 43
women with self-reported blood tests indicating thyroid disease, higher than that reported in
hypothyroidism.
Menstrual and reproductive problems specific to the TSC population remain unreported in
the general population and thus all of these novel findings are relevant to TSC. The true
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menstrual function of the women whose menstrual history was deemed uninformative is
unknown, whether obscured by the use of oral contraceptives or intrauterine contraceptive
device, terminated with reproductive surgery, or simply missing from the analysis. The data
presented above points to an increased risk for a number of menstrual irregularities in women
with TSC in addition to the study question of interest (POF). Furthermore these irregularities
appear to occur with or without a history of seizures or AED use, and outside of correlations to
TSC severity or genetic testing results. At the very least, further attention to reproductive
health is necessary for women with TSC, and further research is needed to further identify
both risk factors and more accurate estimates of the prevalence of such reproductive
disruptions.
TSC Diagnosis
Review of the data characterizing the TSC of these women revealed some noteworthy
results. The mean age of diagnosis of TSC was 15 years, ranging from prenatally to 62 years.
These ages are later than expected, particularly when considering the number of features
present in infancy or early childhood. However, because of variable expressivity of TSC, it is
not uncommon for individuals to have a very mild disease and thus subtle presentation. Adults
are often diagnosed when more severely affected child or family member is ascertained.
Additionally, 103 of women were age 40 or older at diagnosis, and it is plausible that many
went undiagnosed prior to increased access and knowledge of genetic services in medicine
and awareness among practitioners. We analyzed these two groups for significant differences
among those diagnosed at a younger age (less than 18 years), and those diagnosed later in
life (after the age of 18). First, as might be expected, there was a greater severity of TSC in
those individuals diagnosed at a younger age, indicated by a higher prevalence of intellectual
disability, learning disabilities, and autism. Furthermore, there were higher percentages of
angiofibromas, hypopigmented macules, angiomyolipomas, cardiac rhabdomyomas, and
seizures in the individuals who were diagnosed at a younger age. These results are not
surprising as many of these clinical features are clues to the diagnosis of TSC. Additionally, of
the 99 individuals who were diagnosed at a younger age, over 70% of them indicated they did
not have a family history of TSC (this is consistent with the de novo mutation rate), or did not
know. A lack of awareness of a dominant genetic condition in one’s family might also impede a
definitive diagnosis. In contrast, women diagnosed with TSC after the age of 18 had an
increased frequency of blood tests indicating a menopausal state, a higher pregnancy history,
higher report of reproductive menopausal symptoms including hot flashes and night sweats,
higher diagnoses of autoimmune disease, and a higher numbers of reported hysterectomies.
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Some of these findings would be expected in older respondents, and accordingly, the average
age of 82 respondents who were diagnosed at age 18 years or older was 51.1 years (±10.6).
Thus, the findings discussed are more likely to be found in a population of older women.
Despite these possible confounders, the later age of diagnosis in a sample of mostly
independent women who belong to a national support group likely underestimates a more
widespread lack of awareness and diagnosis of affected individuals nationwide, especially
those with mild disease.
Mood Disorders
Another important finding from the data is the high prevalence of mood disorders in
women affected with TSC. Detailed data is presented in Table 18. The diagnoses of anxiety,
depression, obsessive compulsive disorder (OCD), and bipolar disorder (BPD), taken together,
were observed in 93 of women (51.1%). Studies examining psychological distress in TSC
have found anxiety and depression to be the most common, particularly in women [Pulsifer].
Previous studies have found a prevalence of anxiety of up to 56% and depression of up to
43% in adults with TSC [Lewis; Raznahan]. A large contributing factor to this prevalence of
psychiatric illness is the individual’s history of seizures. Individuals with epilepsy in the general
population have higher rates of depression, anxiety, and other mood disorders, and
particularly those individuals with a higher frequency of seizures [Thompson; Kanner]. This
background risk makes medication difficult as individuals are often taking additional
medication to reduce their seizures. In our sample, 57 women (50%) of those with an apparent
mood disorder reported a history of seizures. About 50% of these women reported a seizure
frequency of less than once a year, while about 40% reported frequencies ranging from once
every six months - once a week. Next, as previously discussed, the rates of depression are
also higher in women with a diagnosis of POF [Schmidt], and may present prior to the actual
time of diagnosis. In the general population mood disorders are estimated to affect about 9.5%
of adult individuals, at an average onset of 30 years [NIMH]. Women are more likely to be
affected, particularly those of Caucasian ethnicity, and it is thought that 1 in 8 women will
develop clinical depression in some time during her life [NIMH, 1999]. Therefore, it is likely that
a woman affected with TSC experiencing menstrual irregularities has an even higher risk to
develop mood disorders when compared to any three of these considerations alone. Risk of
psychological problems warrants further attention by clinical providers for women with TSC,
and they should be counseled accordingly and/or referred to appropriate specialists to
optimize their well-being. When we analyzed women reporting a history of mood disorder, we
found statistically significant differences in comparison to women without illness. Provided in
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Table 18, these included higher percentages of hot flashes and night sweats, consistent with a
possible presentation of POF. A higher frequency of reported High blood pressure may be
related to side effects of medication, or found commonly in the general adult US female
population, but this same finding was also a significant difference among our sample of seven
women with possible POF. Regarding mood disorders, we did not observe any differences
directly related to manifestations specific to TSC. It may be that women who have a baseline
risk for mood disorders from gender alone, increased through the presence of a genetic
disorder involving epilepsy, could face a higher risk from problems related to menstrual
dysfunction or reproductive issues. It would be prudent for healthcare providers to address
these issues with women while managing their TSC. Forty-four women (24.2%) reported use
of psychotropic non-seizure medication, and women took an average of 1.5 of these classes of
medicine A significant portion of women who reported mood disorder are not receiving
medication (49 women, or 52.7% of those reporting a mood disorder). Secondly, as multiple
medications are needed and likely contribute to additional side effects which must be
considered in light of the number of medications these women are prescribed for the
management of TSC alone. Perhaps these women need additional psychiatric support, and
would possibly benefit from the use of other services attending to psychiatric illness, including
psychotherapy. It also suggests that not all psychiatric manifestations arise from TSC alone,
and women may be unaware of additional, unrecognized menstrual problems contributing to
their psychiatric health.
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Strengths and Limitations
The present study is strengthened by the use of thorough personal reproductive history,
and numerous questions aimed at addressing other known causes of POF, and menstrual
irregularity. The questionnaire was detailed and thorough. The majority of participants filled it
out sufficiently enough for inclusion in the study.. Furthermore, the data are considered
reliable, reflecting personal histories of mostly independent women of higher socio-economic
status involved in their medical care. Our sample size of 182 presents a good representative
number of women affected with TSC, and allows for the identification of a reproductive
disorder reported to be present in only 1% of women. The prevalence determined from our
study may be an underestimate. A larger sample size would allow the research to identify
whether even more women are affected.
Limitations include those common to self-reported questionnaire data. A number of
women were old enough to make recollection of menstrual history in the 30s more difficult.
Additionally, the use of oral contraceptives could mask other women who may have had
unrecognized menstrual dysfunction. Infertility specialists often diagnose women with POF as
part of an infertility evaluation. As over 40% of women remained single in our sample, and a
number stopped having children by their 30s, fewer women may be aware of underlying
menstrual irregularities. We were also limited in our inability to verify diagnosis of either TSC
or POF in these women. However, when considering dermatological, renal, cardiac,
pulmonary manifestations of TSC and the presence of seizures, we observed the presence of
at least one affected organ system or seizure history in 100% of women. Ninety-three percent
of women had more than one affected organ system or a seizure history, over two-thirds have
manifestations in at least three areas, and 9.34% had manifestations in all five. We would thus
expect these women were indeed affected with TSC. The second issue was addressed by
applying stringent criteria to evaluate menstrual history for the presence of POF. Menstrual
trends of regular cycles to irregular cycles were an initial filter, and women with inconsistent or
contradictory information were further excluded. Additionally, a diagnosis of POF requires
corresponding values of LH and FSH, which we were not able to obtain. These issues and
other missing data may contribute to an underestimate of other women with an unrecognized
progression to menstrual irregularity or POF. Our sample population reflects a bias not
uncommon in study populations ascertained from national support groups, and may be less
reflective of TSC, particularly as our analysis of mostly independent women appearing to have
milder disease was evidenced by the lower percentages of women reporting a history of
seizures, and fewer indications of cognitive or psychiatric impairment. It is expected that 90%
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of individuals with TSC will have or have had seizures, and about half are expected to have
some cognitive impairment or psychiatric disturbance [Prather]. Finally, TSC shows no ethnic
predilection, but our study was primarily conducted on Caucasian women. Additional risk
factors that may or may not be present in other ethnic populations were essentially unstudied
in this research
Future Directions
Data from the present study unveils previously unrecognized gender-specific
manifestations of TSC and highlights a need for future studies assessing the reproductive
health of women with TSC. More work is needed to elucidate the risk of reproductive
dysfunction in women with TSC. It will be important to assess longitudinal FSH and LH levels
in women with TSC from age 30 to 40. Such laboratory studies along with better reproductive
histories would make the diagnosis of POF more definitive and provide a better prevalence in
the TSC population. Women receiving radiation therapy in the brain may need to be monitored
for ovarian function following treatment and recognition of possible effects on the
hypothalamic-pituitary axis. Lastly, referral to reproductive specialists may be important,
particularly to bring attention to other disease separate from more familiar manifestations of
TSC.
Traditional mechanisms of TSC associated manifestations involve loss of heterozygosity
and haploinsufficiency [(Castro; Wilson]. It is unknown which, if either, of these are likely
responsible for the effect on ovarian function observed in the women studied. The original data
from the mouse models suggested that LOH would be the likely mechanism of POF. Complete
loss of either Tsc1 or Tsc2 in primordial follicles led to increased activation of mTORC1 and
the entire population of oocytes [Adkihari 2009, 2010]. The mutant mice were initially fertile
with normal litter sizes; however litter size progressively decreased until POF and infertility
occurred. Our data suggests that similar events may occur in the ovaries of women with TSC.
However, in humans, haploinsufficiency may be a more likely explanation to account for the
gradual and magnitude of decline necessary to deplete ovarian reserve. The data suggest that
it may be useful to study women with TSC for signs of premature ovarian failure and other
reproductive disorders. These data also raise the intriguing possibility that the use of mTORC1
inhibitors may be a potential treatment for TSC-related menstrual dysfunction. Trials of the
compound rapamycin, a potent and specific mTORC1 inhibitor, have shown great promise for
SEGAs, angiomyolipomas, and facial angiofibromas. If up-regulated mTORC1 is
demonstrated to be a main mechanism of POF in women with TSC, then perhaps rapamycin
might be a feasible treatment for this newly appreciated manifestation of TSC. Unfortunately
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the potential teratogenicity of rapamycin might present a problem in its use as a treatment for
POF. Rapamycin is registered as Class C and animal studies have indicated embryotoxicity
and fetotoxicity, which include intrauterine fetal demise, reduced weights, and delayed
ossification. No adequate studies of pregnant women exist, though successful use of this drug
during pregnancy has been reported [Jankowska].
Conclusion
Our study is the first to assess the presence of menstrual irregularities and reproductive
dysfunction in a TSC population. We uncovered a significantly elevated prevalence of POF in
a sample of 182 women belonging to the Tuberous Sclerosis Alliance. The majority of women
were independent and mildly affected with TSC. They responded to a thorough questionnaire
and self-reported history of menstrual health and reproductive function, as well as trends in
menstrual cyclicity. These data were filtered through stringent criteria to determine women
who progress from regular cycles to irregular cycles, consistent with the development of POF.
Additional data on reproductive and menstrual health was used to support the possibility of or
exclude a categorization of possible POF. Nine women were deemed to have possible POF.
This figure is higher than that previously suggested in the general population, and parallels
molecular research reported in conditional knock-out mice models of TSC. The research
suggested dysregulation of mTORC leading to problems in murine ovarian function, and
indeed, this may also be implicated in women’s health. When comparing these 9 women with
possible POF to independent women in the sample population over the age of 30, no
connections to other variables, overall TSC severity, or a history of seizures / anti-epileptic
drugs were found. These results suggest that TSC per se is likely predisposing these women
to POF.
In addition to specific results of POF in this population, we identified other notable
findings, also previously unreported. First, we observed that the women in our sample
experienced a higher rate of miscarriage, and at an earlier age than is expected for the
general population. In our analysis of menstrual trends, we found that over one-third of women
had some sort of irregularity, and may be an underestimate as we could not analyze data for
women using oral contraceptives or those that did not recall their prior menstrual regularity.
Outside of menstrual health, we also found that the women studied had a later age of
diagnosis than is typical for TSC. As would be expected, individuals who were diagnosed
earlier were more likely to have seizures and be dependent. Lastly, the presence of mood
disorders such as depression, anxiety, OCD, and BPD were elevated in our population,
signifying a possible additive effect of gender, the genetic disorder TSC, and menstrual
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irregularities on mental health. Furthermore, not all of these women were receiving
psychotropic medication. More attention is needed to resolve some of these issues with
women’s well-being, in addition to increased awareness of other reproductive issues in women
with TSC. In the absence of clinical data but with stringent menstrual trend criteria, supporting
reproductive data, and reliable self-reporting, our findings present a reasonable possibility of
POF or ovarian insufficiency in women with TSC. However, a lack of reporting and a sample
population with some ascertainment bias calls for further work to elucidate this risk and bring
attention to other issues in these women. The use of clinical laboratory information will further
the research suggesting the possible connection with TSC and POF.
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Appendix A. Survey Questionnaire

Tuberous Sclerosis Complex / Reproductive Health Questionnaire
This questionnaire is designed to learn if Tuberous Sclerosis Complex (TSC) affects a
woman’s reproductive health. Specifically, we are interested in a condition known as
Premature Ovarian Failure (POF), in which the ovaries stop working normally before the age
of 40. Currently very little is known about how TSC might affect ovarian function, but more
information will be helpful to people with TSC. We have designed this questionnaire to learn a
little about you or your affected family member (demographics), about the severity of your
TSC, and about your past and current reproductive health. Please keep in mind no personal
information will be used. We greatly appreciate your help with this research project.
Instructions:
The enclosed envelope includes return postage for one survey. If there is more than
one female with TSC over the age of 18 in your household we ask that you complete a
questionnaire for each individual. You may make a copy of this survey and provide your
own postage to return it. Or you may request another one, either through the TS
Alliance, by emailing tscstudy@yahoo.com, or by phone to Emily Gabitzsch (713 500
5760). We will not keep or share any of your personal information.
Please answer the questions (circle the numbers, responses, or write in as requested) about
you or your affected family member as best as possible and return the questionnaire in the
enclosed addressed envelope.
If you are unsure about an answer or do not wish to respond, please mark “Don’t Know (D/K)”
or leave it blank. Should you have any specific questions about the survey, you can send an
email to tscstudy@yahoo.com for assistance.
These questionnaires are anonymous. Please do not include your name, address or any other
information that would allow us to identify you. Please be aware these questions are for
research purposes only and are not related to the medical supervision by your primary, or
specialty healthcare providers. We thank you very much for sharing this information. Results of
this study will be available through the Tuberous Sclerosis Alliance.
Sincerely,
Michael J. Gambello, MD, PhD
Associate Professor of Pediatrics
UT Health

Emily Gabitzsch, BS
Genetic Counseling Student
UT Health
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*****Is the person filling out this questionnaire affected with TSC?*****
 Yes: please continue to Part 1
 No: please answer all of the questions with respect to the individual with TSC
Part 1 – Demographics:
Age: ___________
1) What is your ethnicity?
 Caucasian, non-Hispanic

Height __________

Weight _________

 African-American
 Hispanic
 Asian
 Other, please specify ___________________________________
2) What is your current marital status?
 Single
 Married
 Divorced
 Widowed
3) Who do you currently live with?
 Alone
 With family members
 With a significant other
 With unrelated individuals in an assisted living environment
 Other, please specify ____________________________________
4) What is the highest level of education you’ve completed?
 Under 12th grade
 Completed 12th grade
 Some college
 Associate’s degree
 Bachelor’s degree
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 Master’s degree or higher
5) What is your current employment status?
 Unemployed
 Employed part-time
 Employed full-time
 Student
 Other _________________________________
6) Optional: Which of the following best describes your approximate household yearly
income?
 Less than $10,000
 $10,000 – $24,999
 $25,000 – $49,999
 $50,000 – $74,999
 $75,000 – $100,000
 More than $100,000
 Prefer not to answer
Part 2 – General and Reproductive Health:
7a) Have you ever had a period? (circle one)
Yes
No (please skip to question 9)
b) If yes, how old were you when you had your first period? ______ years
8a) Have you ever been pregnant? (circle one)
Yes

No (please skip to question 9)

b) How many live births have you had?
c) How many preterm births have you had, if any?
d) Please indicate your age at each delivery, in years
Pregnancy #
1
2
3
4
5
6
7

________
________

My age at delivery, in years
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e) Have you ever had a miscarriage? (circle one)
Yes
No
Don’t Know
f) If yes, please indicate your age at each miscarriage
Miscarriage #
My age, in years
1
2
3
4
5
6
g) Have you ever had a voluntary termination? (circle one)
Yes
h) If yes, how many? ________

No

Don’t Know

9) The chart below is about your menstrual history, since you first got your period.
Please circle the appropriate response in each column for each range.
**PLEASE FILL OUT THE CHART FOR EACH AGE RANGE UP TO AND INCLUDING
YOUR CURRENT AGE.**For example, if you are 22, please only complete rows 1 and 2.
If you are 36, please complete rows 1 through 5, etc.
Age
range

For the MAJORITY of this age range,
my periods were :

For the MAJORITY of this age
range, I took :

(in
years)

Regular:
10
or more periods
per year

Oral contraceptive pills or had an
intrauterine contraceptive device
(IUD) in place:

1

16-20

Regular

Irregular

Yes

No

2

21-25

Regular

Irregular

Yes

No

3

26-30

Regular

Irregular

Yes

No

4

31-35

Regular

Irregular

Yes

No

5

36

Regular

Irregular

Yes

No

6

37

Regular

Irregular

Yes

No

7

38

Regular

Irregular

Yes

No

8

39

Regular

Irregular

Yes

No

9

40

Regular

Irregular

Yes

No

.
Row
#

OR

Irregular: 9
or less periods
per year, or 0
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10) Please indicate what medications, supplements, and/or vitamins you are currently
taking. Please specify the name and dose, if known.
Name

Dose

How often you take this medicine

11) Please choose the appropriate response in EACH row to indicate if you have
experienced any of the following symptoms, within the past year or at any time, and
indicate how long those symptoms continued, in years.

Symptom
Hot Flashes
Night Sweats
Excess body hair
Acne
High blood pressure
Milky discharge from the breasts
(when not breastfeeding)
Weight gain over 25 pounds,
not including gain during pregnancy

Within the past
year

Ever
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

Yes

No

Yes

No

Yes

No

Overall
duration
(in
years)

12) Have you ever been diagnosed with any of the following? Please circle the
appropriate response in EACH row. To indicate who diagnosed you, please select from:
General physician, Infertility specialist, endocrinologist, Ob-Gyn, Other, specify:
Name

Diagnosed

Age
(years)

Diagnosed By

Premature Ovarian Failure
Yes No Don’t Know
Polycystic Ovarian Syndrome
Yes No Don’t Know
Amenorrhea
Yes No Don’t Know
(no menstrual period)
Infertility
Yes No Don’t Know
Anorexia
Yes No Don’t Know
Galactosemia
Yes No Don’t Know
Turner Syndrome
Yes No Don’t Know
Addison Disease
Yes No Don’t Know
Autoimmune Disorder (i.e.,
Yes No Don’t Know
Lupus)
13) Have you ever had a blood test showing the following? Please circle the appropriate
response for EACH row.
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Menopausal state
Thyroid disease
High testosterone levels

Yes
Yes
Yes

No
No
No

Don’t Know
Don’t Know
Don’t Know

14) Have you had any of the following surgeries/procedures? Please circle the
appropriate response in EACH row.
Procedure

Performed

Hysterectomy (removal of uterus)
Oophorectomy (removal of ovaries)
Radiation therapy
Chemotherapy

Yes

No

Don’t Know

Yes
Yes
Yes

No
No
No

Don’t Know
Don’t Know
Don’t Know

Age when performed
(in years)

15 )Please indicate if you have any family members who have also been diagnosed with
any of the conditions below.
Please indicate their relationship to you, and the age in years or decade of life (teens,
30s, 40, etc.) when they were diagnosed.
Relationship to you

Diagnosis

Age at
diagnosis

1.
Premature Ovarian
Failure (menopause
before age 40)
Autoimmune
disorders (i.e. Lupus,
or under/overactive
thyroid, rheumatoid
arthritis)

No one in
my family

Don’t Know 2.
3.
1.

No one in
my family

Don’t Know

2.
3.
1.

Fragile X syndrome

No one in
my family

Don’t Know 2.
3.

Part 3 – Tuberous Sclerosis Complex (TSC):
16) How old were you when you were diagnosed with TSC (age, in years)? __________
17a) Do you have any family members who also have TSC? (circle one)
Yes

No

Don’t Know

b) If yes, please indicate their relationship to you. Please provide their specific
age in years, or decade of life (teens, 20s, 30s, etc.) when they were diagnosed.
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Relationship to you
1.

Age at diagnosis

2.
3.
4.

18a) Have you or a family member ever had genetic testing? (circle one)
Yes

No

Don’t Know

b) If yes, what were the results? (check one)
 Mutation in TSC1
 Mutation in TSC2
 No mutation identified
 Other mutation, please specify: ___________________________
 Don’t Know
19a) Do you have (or have you ever had) a subependymal giant cell astrocytoma
(SEGA)? (circle one)
Yes

No (skip to #20)

Don’t Know

b) If yes, have you received treatment for your SEGA? (circle one)
Yes

No

Don’t

Know
c) If yes, what type of treatment did you receive? (check all that apply)





Surgery
Radiation
Medication/chemotherapy (including rapamycin)
Other, please specify: ____________________________________

20a) Have you ever had seizures? (circle one)
Yes

No (skip to #21)

Don’t Know
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b) If yes, please indicate the age (in years) at which they first started ________
c) How often do you have seizures? (please check only one)






At least once a day
At least once a week, but not daily
At least once a month, but not weekly
At least once every six months, but not every month
Less than once a year

d) Have you ever had surgery to control your seizures? (circle one)
Yes

No

Don’t know

e) Please indicate the medications you currently take for your seizures and how
long (in years) you’ve been taking them. Using a scale from 1 – 3, please indicate
how effective you believe the medicines are:
1 (did not work well)
Medication

2 (neutral) 3 (worked well)

# years

____

Effectiveness (circle one)

1.

1

2

3

2.

1

2

3

3.

1

2

3

4.

1

2

3

5.

1

2

3

f) Please indicate the medications you have taken in the past for your seizures
and how long (in years) you took them for. Using a scale from 1 – 3, please
indicate how effective you believe these medicines were:
1 (did not work well)

Medication

2 (neutral) 3 (worked well)

# years

____

Effectiveness (circle one)

1.

1

2

3

2.

1

2

3

3.

1

2

3

4.

1

2

3

5.

1

2

3
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21) Have you ever been diagnosed with the following? Please circle the appropriate
response for each row and indicate your age of diagnosis or when symptoms began.
Name
Learning disability
ADHD/ADD
Autism
Bipolar Disorder
Depression
Dyslexia
Mental Retardation
Obsessive Compulsive
Disorder (OCD)
Other, please specify
___________________

Currently

Ever

Age diagnosed
(years)

Don’t Know

Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
No
No
No
No
No
No

Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know
Don’t Know

Yes

No

Yes

No

Don’t Know

Yes

No

Yes

No

Don’t Know

22) Do you have or have you ever had the following? Please circle the appropriate
response in each row.
Name
Facial angiofibromas/adenoma sebaceum/ red
spots on the face
Ash leaf spots/white birth marks or patches
Fingernail/toenail tumors

Currently

Ever

Don’t Know

Yes

No

Yes

No

Don’t Know

Yes
Yes

No
No

Yes
Yes

No
No

Don’t Know
Don’t Know

23) Have you ever been diagnosed with the following? Please circle the appropriate
response for each row and indicate your age at diagnosis.
Name
Renal (kidney) cysts
Angiomyolypoma
Kidney (renal) cancer

Currently
Yes
Yes
Yes

No
No
No

Ever
Yes
Yes
Yes

Don’t Know
No
No
No

Age diagnosed
(years)

Don’t Know
Don’t Know
Don’t Know

24) Have you ever been diagnosed with the following? Please circle the appropriate
response for each row and indicate your age of diagnosis or when symptoms began.
Name
Pulmonary (lung) cysts
Lymphangioleiomyomatosis
(LAM)
I experience shortness of
breath going up one flight of
stairs

Currently

Ever

Don’t Know

Yes

No

Yes

No

Don’t Know

Yes

No

Yes

No

Don’t Know

Yes

No

Yes

No

Don’t Know
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Age of diagnosis or
symptom onset
(years)

25) Have you ever been diagnosed with the following? Please circle the appropriate
response for each row and indicate your age when each was noticed.
Name
Rhabdomyomas/
Heart tumor
Irregular heartbeat

Currently

Ever

Don’t Know

Yes

No

Yes

No

Don’t Know

Yes

No

Yes

No

Don’t Know

Age noticed (years)

26) Are there any other medical problems related to TSC you would like to mention?

Conclusion
Congratulations! You are finished with the Questionnaire. Please place it in the addressed,
stamped envelope and mail it back to us. We thank you again for sharing your time and health
information. We hope the results of this study will benefit women with TSC.
Michael J. Gambello, MD, PhD

Emily Gabitzsch, BS
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Appendix B
Characteristics of the dependent woman with possible POF
Briefly, the one dependent woman whose menstrual cycles demonstrated a
progression from regular to irregular will be described. As mentioned above, she was not
included in the group of seven women as we chose to compare to independent women only.
This eighth woman was 46 years old when she had her questionnaire completed by another
individual. She is African-American and single, lives with family, and is unemployed; she has
completed some college. Her reported age of menarche was not provided to us in the
questionnaire. This woman has no reported pregnancies. She did experience normal cyclicity
between the ages of 16 and 35, but after age 36 irregular cycles were reported; she has never
used oral contraceptives. Of note, she did have a hysterectomy and oophorectomy at age 37.
Our participant was also reported to have radiation therapy at age 24, but a specific

We do not have menstrual reporting for ages Her reproductive history is negative for
blood tests, diagnoses, symptoms, or surgeries, per report. This woman does have a history of
seizures, with an onset of 6 months. She experiences seizures approximately once per month.
In the past, this woman used levetiracetam and topiramate for seizure control, each for one
month. Her current medications include valproic acid, phenobarbital, (taken for 31 years), and
clonazepam (taken for 16 years). She did receive genetic testing and her results were reported
as no mutation identified. Interestingly, the only clinical manifestations of TSC reported for this
woman were angiofibromas and hypopigmented macules. She also has diagnoses of autism
and mental retardation, both at age 2. This woman meets the menstrual history criteria set for
a categorization of possible POF. She does lack additional reproductive data to solidify this
possibility; however, she does not have contradictory information. It is possible that her current
use of medication for seizures could contribute to her menstrual irregularity as discussed
above. As a general comparison to other dependent women between the ages of 30 and 40,
she appears to differ only in the small number of TSC manifestations, as she does not exhibit
findings in the cardiac, renal, or pulmonary systems. Our choice to exclude this woman from
the analysis was based on her differences due to her being dependent, but at a glance, she
does not appear to exhibit significant differences.
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